: The AMEDEO Literature Guide

Home The Word Brain

My Amedeo

FAQ

Privacy

About

Flying Publisher

The Angels Initiative

Stroke prevention

Multiple Sclerosis

Free Subscription

Articles published in Mult Scler
Retrieve available abstracts of 418 articles:
HTML format

Single Articles

October 2022

PAUWELS A, Van Schependom J, Devolder L, Van Remoortel A, et al
Plasma glial fibrillary acidic protein and neurofilament light chain in relation to disability worsening in multiple sclerosis.
Mult Scler. 2022;28:1685-1696.
PubMed Abstract available

FORD CC, Cohen JA, Goodman AD, Lindsey JW, et al
Early versus delayed treatment with glatiramer acetate: Analysis of up to 27 years of continuous follow-up in a US open-label extension study.
Mult Scler. 2022;28:1729-1743.
PubMed Abstract available

HARDY TA, Guo Y, Flanagan EP, Lucchinetti CF, et al
The clinical spectrum of haemorrhagic CNS inflammatory demyelinating lesions.
Mult Scler. 2022;28:1710-1718.
PubMed Abstract available

CAPANNA M, Signori A, Sormani MP
Is the effect of drugs in progressive MS only due to an effect on inflammation? A subgroup meta-analysis of randomised trials.
Mult Scler. 2022;28:1744-1751.
PubMed Abstract available

ZARGHAMI A, van der Mei I, Hussain MA, Claflin SB, et al
Long-term trajectories of employment status, workhours and disability support pension status, after a first episode of CNS demyelination.
Mult Scler. 2022;28:1793-1807.
PubMed Abstract available

GRAF J, Ng HS, Zhu F, Zhao Y, et al
Emergency department use by persons with MS: A population-based descriptive study with a focus on infection-related visits.
Mult Scler. 2022;28:1825-1828.
PubMed Abstract available

GAETANI L, Schoonheim MM
Serum neurofilament light chain predicts cognitive worsening in secondary progressive multiple sclerosis better than brain MRI measures.
Mult Scler. 2022;28:1831-1833.
PubMed

KOUBIYR I, Broeders TA, Deloire M, Brochet B, et al
Altered functional brain states predict cognitive decline 5 years after a clinically isolated syndrome.
Mult Scler. 2022;28:1973-1982.
PubMed Abstract available

ARNOLD DL, Sprenger T, Bar-Or A, Wolinsky JS, et al
Ocrelizumab reduces thalamic volume loss in patients with RMS and PPMS.
Mult Scler. 2022;28:1927-1936.
PubMed Abstract available

BESSING B, Claflin SB, Taylor BV, Blizzard L, et al
Estimating the impact of work difficulties, work self-efficacy and work psychological safety on MS-related work productivity loss.
Mult Scler. 2022;28:1983-1996.
PubMed Abstract available

September 2022

BUHLER A, Wolbers M, Model F, Wang Q, et al
Recurrent disability progression endpoints in multiple sclerosis clinical trials.
Mult Scler. 2022 Sep 30:13524585221125382. doi: 10.1177/13524585221125382.
PubMed Abstract available

ALEXANDER S, Braisher M, Tur C, Chataway J, et al
The mSteps pilot study: Analysis of the distance walked using a novel smartphone application in multiple sclerosis.
Mult Scler. 2022 Sep 30:13524585221124043. doi: 10.1177/13524585221124043.
PubMed Abstract available

STRIK M, Eijlers AJ, Dekker I, Broeders TA, et al
Sensorimotor network dynamics predict decline in upper and lower limb function in people with multiple sclerosis.
Mult Scler. 2022 Sep 30:13524585221125372. doi: 10.1177/13524585221125372.
PubMed Abstract available

SARACENO L, Pirro F, Stigliano R, Agostoni EC, et al
Acute idiosyncratic liver injury after Cladribine treatment for multiple sclerosis: first case report and review on associated hepatic disorders.
Mult Scler. 2022 Sep 28:13524585221125360. doi: 10.1177/13524585221125360.
PubMed Abstract available

BRUIJSTENS AL, Stingl C, Guzel C, Stoop MP, et al
Neurodegeneration and humoral response proteins in cerebrospinal fluid associate with pediatric-onset multiple sclerosis and not monophasic demyelinating syndromes in childhood.
Mult Scler. 2022 Sep 24:13524585221125369. doi: 10.1177/13524585221125369.
PubMed Abstract available

POL-PATIL J, Glanz B, Safar L, Misasi E, et al
MeTooMS: Sexual, physical, and emotional abuse experience among women with multiple sclerosis.
Mult Scler. 2022 Sep 24:13524585221122169. doi: 10.1177/13524585221122169.
PubMed Abstract available

CHANG I, Kappos L, Giovannoni G, Calabresi PA, et al
Overall Disability Response Score: An integrated endpoint to assess disability improvement and worsening over time in patients with multiple sclerosis.
Mult Scler. 2022 Sep 21:13524585221114997. doi: 10.1177/13524585221114997.
PubMed Abstract available

COHEN JA, Lublin FD, Lock C, Pelletier D, et al
Evaluation of neurotrophic factor secreting mesenchymal stem cells in progressive multiple sclerosis.
Mult Scler. 2022 Sep 14:13524585221122156. doi: 10.1177/13524585221122156.
PubMed Abstract available

VAN LIEROP ZY, Noteboom S, Steenwijk MD, van Dam M, et al
Neurofilament-light and contactin-1 association with long-term brain atrophy in natalizumab-treated relapsing-remitting multiple sclerosis.
Mult Scler. 2022 Sep 3:13524585221118676. doi: 10.1177/13524585221118676.
PubMed Abstract available

MCGINLEY MP, Lapin B
The value of patient-reported outcome measures for multiple sclerosis.
Mult Scler. 2022;28:1489-1490.
PubMed

STRIJBIS EM, Repovic P, Mostert J, Bowen JD, et al
The MSIS-29 and SF-36 as outcomes in secondary progressive MS trials.
Mult Scler. 2022;28:1606-1619.
PubMed Abstract available

KLISTORNER S, Barnett MH, Graham SL, Wang C, et al
The expansion and severity of chronic MS lesions follows a periventricular gradient.
Mult Scler. 2022;28:1504-1514.
PubMed Abstract available

XIANG B, Brier MR, Kanthamneni M, Wen J, et al
Tissue damage detected by quantitative gradient echo MRI correlates with clinical progression in non-relapsing progressive MS.
Mult Scler. 2022;28:1515-1525.
PubMed Abstract available

THEBAULT S, Bose G, Booth R, Freedman MS, et al
Serum neurofilament light in MS: The first true blood-based biomarker?
Mult Scler. 2022;28:1491-1497.
PubMed Abstract available

PORTACCIO E, Amato MP
Reliable change indices for cognitive assessment of patients with multiple sclerosis.
Mult Scler. 2022 Sep 1:13524585221116273. doi: 10.1177/13524585221116273.
PubMed

August 2022

MEATON I, Altokhis A, Allen CM, Clarke MA, et al
Paramagnetic rims are a promising diagnostic imaging biomarker in multiple sclerosis.
Mult Scler. 2022 Aug 26:13524585221118677. doi: 10.1177/13524585221118677.
PubMed Abstract available

BROWNLEE WJ, Wolf C, Hartung HP, Dingermann T, et al
Use of follow-on disease-modifying treatments for multiple sclerosis: Consensus recommendations.
Mult Scler. 2022 Aug 24:13524585221116269. doi: 10.1177/13524585221116269.
PubMed Abstract available

ALTOKHIS AI, Hibbert AM, Allen CM, Mougin O, et al
Longitudinal clinical study of patients with iron rim lesions in multiple sclerosis.
Mult Scler. 2022 Aug 24:13524585221114750. doi: 10.1177/13524585221114750.
PubMed Abstract available

YOUNG CA, Mills RJ, Langdon D, Rog DJ, et al
Measuring coping in multiple sclerosis: The Coping Index-MS.
Mult Scler. 2022 Aug 24:13524585221114004. doi: 10.1177/13524585221114004.
PubMed Abstract available

IAFFALDANO P, Lucisano G, Guerra T, Patti F, et al
Towards a validated definition of the clinical transition to secondary progressive multiple sclerosis: A study from the Italian MS Register.
Mult Scler. 2022 Aug 15:13524585221114007. doi: 10.1177/13524585221114007.
PubMed Abstract available

BLYAU S, Koubiyr I, Saranathan M, Coupe P, et al
Differential vulnerability of thalamic nuclei in multiple sclerosis.
Mult Scler. 2022 Aug 12:13524585221114247. doi: 10.1177/13524585221114247.
PubMed Abstract available

CONWAY SE, Pua DKA, Holroyd KB, Galetta K, et al
Neurologic disease activity in people with multiple sclerosis treated with immune checkpoint inhibitors.
Mult Scler. 2022 Aug 11:13524585221117949. doi: 10.1177/13524585221117949.
PubMed Abstract available

WILLIAMS T, Tur C, Eshaghi A, Doshi A, et al
Serum neurofilament light and MRI predictors of cognitive decline in patients with secondary progressive multiple sclerosis: Analysis from the MS-STAT randomised controlled trial.
Mult Scler. 2022 Aug 9:13524585221114441. doi: 10.1177/13524585221114441.
PubMed Abstract available

CIFTCI KAVAKLIOGLU B, Erdman L, Goldenberg A, Kavaklioglu C, et al
Machine learning classification of multiple sclerosis in children using optical coherence tomography.
Mult Scler. 2022 Aug 9:13524585221112605. doi: 10.1177/13524585221112605.
PubMed Abstract available

UCCELLI A, Freedman MS
Therapy with mesenchymal stem cell transplantation in multiple sclerosis is ready for prime time: No.
Mult Scler. 2022;28:1326-1328.
PubMed

PERUZZOTTI-JAMETTI L, Pluchino S
Therapy with mesenchymal stem cell transplantation in multiple sclerosis ready for prime time: Commentary.
Mult Scler. 2022;28:1328-1329.
PubMed

KARUSSIS D, Kassis I, Petrou P
Therapy with mesenchymal stem cell transplantation in multiple sclerosis is ready for prime time: YES.
Mult Scler. 2022;28:1324-1326.
PubMed

SESEL AL, Sharpe L, Beadnall HN, Barnett MH, et al
A randomized controlled trial of a web-based mindfulness programme for people with MS with and without a history of recurrent depression.
Mult Scler. 2022;28:1392-1401.
PubMed Abstract available

July 2022

TAGGE IJ, Leppert IR, Fetco D, Campbell JS, et al
Permanent tissue damage in multiple sclerosis lesions is associated with reduced pre-lesion myelin and axon volume fractions.
Mult Scler. 2022 Jul 28:13524585221110585. doi: 10.1177/13524585221110585.
PubMed Abstract available

ZHONG M, van der Walt A, Monif M, Hodgkinson S, et al
Prediction of relapse activity when switching to cladribine for multiple sclerosis.
Mult Scler. 2022 Jul 27:13524585221111677. doi: 10.1177/13524585221111677.
PubMed Abstract available

KLISTORNER S, Barnett MH, Klistorner A
Mechanisms of central brain atrophy in multiple sclerosis.
Mult Scler. 2022 Jul 21:13524585221111684. doi: 10.1177/13524585221111684.
PubMed Abstract available

JOHNSSON M, Farman HH, Blennow K, Zetterberg H, et al
No increase of serum neurofilament light in relapsing-remitting multiple sclerosis patients switching from standard to extended-interval dosing of natalizumab.
Mult Scler. 2022 Jul 20:13524585221108080. doi: 10.1177/13524585221108080.
PubMed Abstract available

MAGYARI M, Joensen H, Kopp TI, Pontieri L, et al
Changes in prognosis of the Danish multiple sclerosis population over time.
Mult Scler. 2022 Jul 13:13524585221110582. doi: 10.1177/13524585221110582.
PubMed Abstract available

KRIEGER SC, Antoine A, Sumowski JF
EDSS 0 is not normal: Multiple sclerosis disease burden below the clinical threshold.
Mult Scler. 2022 Jul 13:13524585221108297. doi: 10.1177/13524585221108297.
PubMed Abstract available

ANNA KARIN H, Erik S, Tim S, Lars F, et al
The impact of bariatric surgery on disease activity and progression of multiple sclerosis: A nationwide matched cohort study.
Mult Scler. 2022 Jul 7:13524585221107095. doi: 10.1177/13524585221107095.
PubMed Abstract available

LADAKIS DC, Yao PJ, Vreones M, Blommer J, et al
Mitochondrial measures in neuronally enriched extracellular vesicles predict brain and retinal atrophy in multiple sclerosis.
Mult Scler. 2022 Jul 5:13524585221106290. doi: 10.1177/13524585221106290.
PubMed Abstract available

MANUEL ESCOBAR J, Cortese M, Edan G, Freedman MS, et al
Body mass index as a predictor of MS activity and progression among participants in BENEFIT.
Mult Scler. 2022;28:1277-1285.
PubMed Abstract available

W KOCH M, Mostert J, Repovic P, Bowen JD, et al
Impact of clinical outcomes and imaging measures on health-related quality of life in secondary progressive MS.
Mult Scler. 2022;28:1286-1298.
PubMed Abstract available

ANDERSEN JB, Wandall-Holm MF, Andersen PK, Sellebjerg F, et al
Pregnancy in women with MS: Impact on long-term disability accrual in a nationwide Danish Cohort.
Mult Scler. 2022;28:1239-1247.
PubMed Abstract available

GIOVANNONI G, Singer BA, Issard D, Jack D, et al
Durability of no evidence of disease activity-3 (NEDA-3) in patients receiving cladribine tablets: The CLARITY extension study.
Mult Scler. 2022;28:1219-1228.
PubMed Abstract available

EISELE P, Wittayer M, Weber CE, Platten M, et al
Impact of disease-modifying therapies on evolving tissue damage in iron rim multiple sclerosis lesions.
Mult Scler. 2022 Jul 1:13524585221106338. doi: 10.1177/13524585221106338.
PubMed Abstract available

June 2022

PROUSKAS SE, Schoonheim MM, Huiskamp M, Steenwijk MD, et al
A randomized trial predicting response to cognitive rehabilitation in multiple sclerosis: Is there a window of opportunity?
Mult Scler. 2022 Jun 28:13524585221103134. doi: 10.1177/13524585221103134.
PubMed Abstract available

CREE BA, Selmaj KW, Steinman L, Comi G, et al
Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis: Up to 5 years of follow-up in the DAYBREAK open-label extension trial.
Mult Scler. 2022 Jun 28:13524585221102584. doi: 10.1177/13524585221102584.
PubMed Abstract available

MARASTONI D, Crescenzo F, Pisani AI, Zuco C, et al
Two years' effect of dimethyl fumarate on focal and diffuse gray matter pathology in multiple sclerosis.
Mult Scler. 2022 Jun 28:13524585221104014. doi: 10.1177/13524585221104014.
PubMed Abstract available

MAGNE F, Cellerino M, Balletto E, Aluan K, et al
Anti-SARS-CoV-2 monoclonal antibodies for the treatment of active COVID-19 in multiple sclerosis: An observational study.
Mult Scler. 2022 Jun 28:13524585221103787. doi: 10.1177/13524585221103787.
PubMed

HEMOND CC, Baek J, Ionete C, Reich DS, et al
Paramagnetic rim lesions are associated with pathogenic CSF profiles and worse clinical status in multiple sclerosis: A retrospective cross-sectional study.
Mult Scler. 2022 Jun 24:13524585221102921. doi: 10.1177/13524585221102921.
PubMed Abstract available

GARJANI A, Liu BJ, Allen CM, Gunzler DD, et al
Decentralised clinical trials in multiple sclerosis research.
Mult Scler. 2022 Jun 23:13524585221100401. doi: 10.1177/13524585221100401.
PubMed Abstract available

MAAROUF A, Audoin B, Gherib S, El Mendili MM, et al
Grey-matter sodium concentration as an individual marker of multiple sclerosis severity.
Mult Scler. 2022 Jun 20:13524585221102587. doi: 10.1177/13524585221102587.
PubMed Abstract available

LAZZAROTTO A, Tonietto M, Poirion E, Battaglini M, et al
Clinically relevant profiles of myelin content changes in patients with multiple sclerosis: A multimodal and multicompartment imaging study.
Mult Scler. 2022 Jun 16:13524585221096975. doi: 10.1177/13524585221096975.
PubMed Abstract available

CHO EB, Yeo Y, Jung JH, Jeong SM, et al
Acute myocardial infarction risk in multiple sclerosis and neuromyelitis optica spectrum disorder: A nationwide cohort study in South Korea.
Mult Scler. 2022 Jun 13:13524585221096964. doi: 10.1177/13524585221096964.
PubMed Abstract available

AL-LOUZI O, Manukyan S, Donadieu M, Absinta M, et al
Lesion size and shape in central vein sign assessment for multiple sclerosis diagnosis: An in vivo and postmortem MRI study.
Mult Scler. 2022 Jun 8:13524585221097560. doi: 10.1177/13524585221097560.
PubMed Abstract available

SCHMIERER K, Wiendl H, Oreja-Guevara C, Centonze D, et al
Varicella zoster virus and influenza vaccine antibody titres in patients from MAGNIFY-MS who were treated with cladribine tablets for highly active relapsing multiple sclerosis.
Mult Scler. 2022 Jun 7:13524585221099413. doi: 10.1177/13524585221099413.
PubMed

BRUNE S, Hogestol EA, de Rodez Benavent SA, Berg-Hansen P, et al
Serum neurofilament light chain concentration predicts disease worsening in multiple sclerosis.
Mult Scler. 2022 Jun 4:13524585221097296. doi: 10.1177/13524585221097296.
PubMed Abstract available

LEAVITT VM, Dworkin JD, Buyukturkoglu K, Riley CS, et al
Summary metrics of memory subnetwork functional connectivity alterations in multiple sclerosis.
Mult Scler. 2022 Jun 4:13524585221099169. doi: 10.1177/13524585221099169.
PubMed Abstract available

BEREK K, Hegen H, Hocher J, Auer M, et al
Retinal layer thinning as a biomarker of long-term disability progression in multiple sclerosis.
Mult Scler. 2022 Jun 2:13524585221097566. doi: 10.1177/13524585221097566.
PubMed Abstract available

CARCAMO C, Ciampi E
Low-dose rituximab should be used for treating MS in resource-limited settings: Commentary.
Mult Scler. 2022;28:1032-1033.
PubMed

PIEHL F, Mathew T
Low-dose rituximab should be used for treating MS in resource-limited settings: Yes.
Mult Scler. 2022;28:1028-1029.
PubMed

MATEEN FJ
Low-dose rituximab should be used for treating MS in resource-limited settings: No.
Mult Scler. 2022;28:1030-1032.
PubMed

PODDA J, Tacchino A, Pedulla L, Monti Bragadin M, et al
Focus on neglected features of cognitive rehabilitation in MS: Setting and mode of the treatment.
Mult Scler. 2022;28:1009-1019.
PubMed Abstract available

May 2022

COFRE LIZAMA LE, Strik M, Van der Walt A, Kilpatrick TJ, et al
Gait stability reflects motor tracts damage at early stages of multiple sclerosis.
Mult Scler. 2022 May 21:13524585221094464. doi: 10.1177/13524585221094464.
PubMed Abstract available

FADDA G, Waters P, Woodhall M, Brown RA, et al
Serum MOG-IgG in children meeting multiple sclerosis diagnostic criteria.
Mult Scler. 2022 May 17:13524585221093789. doi: 10.1177/13524585221093789.
PubMed Abstract available

GONZALEZ-MARTINEZ A, Bose G, Chitnis T
Anti-CGRP therapies for migraine in multiple sclerosis patients.
Mult Scler. 2022 May 14:13524585221096353. doi: 10.1177/13524585221096353.
PubMed

SCHWARZ T, Otto C, Jones TC, Pache F, et al
Preserved T cell responses to SARS-CoV-2 in anti-CD20 treated multiple sclerosis.
Mult Scler. 2022 May 14:13524585221094478. doi: 10.1177/13524585221094478.
PubMed Abstract available

LEUNG MW, Bazelier MT, Souverein PC, Uitdehaag BM, et al
Mapping the risk of infections in patients with multiple sclerosis: A multi-database study in the United Kingdom Clinical Practice Research Datalink GOLD and Aurum.
Mult Scler. 2022 May 14:13524585221094218. doi: 10.1177/13524585221094218.
PubMed Abstract available

ALMRAMHI MM, Storm CS, Kia DA, Coneys R, et al
The role of body fat in multiple sclerosis susceptibility and severity: A Mendelian randomisation study.
Mult Scler. 2022 May 14:13524585221092644. doi: 10.1177/13524585221092644.
PubMed Abstract available

CHIARAVALLOTI ND, DeLuca J, Salter A, Amato MP, et al
The relationship between processing speed and verbal and non-verbal new learning and memory in progressive multiple sclerosis.
Mult Scler. 2022 May 9:13524585221088190. doi: 10.1177/13524585221088190.
PubMed Abstract available

MANGLANI HR, Fisher ME, Duraney EJ, Nicholas JA, et al
A promising cognitive screener in multiple sclerosis: The NIH toolbox cognition battery concords with gold standard neuropsychological measures.
Mult Scler. 2022 May 9:13524585221088731. doi: 10.1177/13524585221088731.
PubMed Abstract available

VALSASINA P, Gobbi C, Zecca C, Rovira A, et al
Characterizing 1-year development of cervical cord atrophy across different MS phenotypes: A voxel-wise, multicentre analysis.
Mult Scler. 2022;28:885-899.
PubMed Abstract available

ROSENSTEIN I, Axelsson M, Novakova L, Blennow K, et al
Exploring CSF neurofilament light as a biomarker for MS in clinical practice; a retrospective registry-based study.
Mult Scler. 2022;28:872-884.
PubMed Abstract available

ACTRIMS Forum 2022.
Mult Scler. 2022;28.
PubMed

April 2022

SPRENGER T, Kappos L, Sormani MP, Miller AE, et al
Effects of teriflunomide treatment on cognitive performance and brain volume in patients with relapsing multiple sclerosis: Post hoc analysis of the TEMSO core and extension studies.
Mult Scler. 2022 Apr 29:13524585221089534. doi: 10.1177/13524585221089534.
PubMed Abstract available

DEGRAEVE B, Sequeira H, Mecheri H, Lenne B, et al
Corpus callosum damage to account for cognitive, affective, and social-cognitive dysfunctions in multiple sclerosis: A model of callosal disconnection syndrome?
Mult Scler. 2022 Apr 27:13524585221091067. doi: 10.1177/13524585221091067.
PubMed Abstract available

MANZANO GS, Rice DR, Klawiter EC, Matiello M, et al
Anti-SARS-CoV-2 monoclonal antibodies for the treatment of active COVID-19 in multiple sclerosis: An observational study.
Mult Scler. 2022 Apr 27:13524585221092309. doi: 10.1177/13524585221092309.
PubMed Abstract available

ZABALZA A, Arrambide G, Otero-Romero S, Pappolla A, et al
Is humoral and cellular response to SARS-CoV-2 vaccine modified by DMT in patients with multiple sclerosis and other autoimmune diseases?
Mult Scler. 2022 Apr 27:13524585221089540. doi: 10.1177/13524585221089540.
PubMed Abstract available

SIMONEAU G, Pellegrini F, Debray TP, Rouette J, et al
Recommendations for the use of propensity score methods in multiple sclerosis research.
Mult Scler. 2022 Apr 6:13524585221085733. doi: 10.1177/13524585221085733.
PubMed Abstract available

CREE BA, Arnold DL, Fox RJ, Gold R, et al
Long-term efficacy and safety of siponimod in patients with secondary progressive multiple sclerosis: Analysis of EXPAND core and extension data up to >5 years.
Mult Scler. 2022 Apr 5:13524585221083194. doi: 10.1177/13524585221083194.
PubMed Abstract available

KALINCIK T, Kister I, Bacon TE, Malpas CB, et al
Multiple Sclerosis Severity Score (MSSS) improves the accuracy of individualized prediction in MS.
Mult Scler. 2022 Apr 3:13524585221084577. doi: 10.1177/13524585221084577.
PubMed Abstract available

MOCCIA M, Affinito G, Ronga B, Giordana R, et al
Emergency medical care for multiple sclerosis: A five-year population study in the Campania Region (South Italy).
Mult Scler. 2022;28:597-607.
PubMed Abstract available

GRATCH D, Zhovtis Ryerson L
Stable multiple sclerosis patients on anti-CD20 therapy should go on extended interval dosing-Commentary.
Mult Scler. 2022;28:695-696.
PubMed

INES CIPLEA A, Kurzeja A, Thiel S, Haben S, et al
Eighteen-month safety analysis of offspring breastfed by mothers receiving glatiramer acetate therapy for relapsing multiple sclerosis - COBRA study.
Mult Scler. 2022 Apr 1:13524585221083982. doi: 10.1177/13524585221083982.
PubMed Abstract available

TZANETAKOS D, Tzartos JS, Vakrakou AG, Breza M, et al
Cortical involvement and leptomeningeal inflammation in myelin oligodendrocyte glycoprotein antibody disease: A three-dimensional fluid-attenuated inversion recovery MRI study.
Mult Scler. 2022;28:718-729.
PubMed Abstract available

KLISTORNER S, Barnett MH, Yiannikas C, Barton J, et al
Expansion of chronic MS lesions is associated with an increase of radial diffusivity in periplaque white matter.
Mult Scler. 2022;28:697-706.
PubMed Abstract available

KIM KH, Kim SH, Park NY, Hyun JW, et al
Reappraisal of CSF-specific oligoclonal bands in Asia.
Mult Scler. 2022;28:665-668.
PubMed Abstract available

KUHLE J, Daizadeh N, Benkert P, Maceski A, et al
Sustained reduction of serum neurofilament light chain over 7 years by alemtuzumab in early relapsing-remitting MS.
Mult Scler. 2022;28:573-582.
PubMed Abstract available

BAJRAMI A, Magliozzi R, Pisani AI, Pizzini FB, et al
Volume changes of thalamus, hippocampus and cerebellum are associated with specific CSF profile in MS.
Mult Scler. 2022;28:550-560.
PubMed Abstract available

VALENTINE TR, Alschuler KN, Ehde DM, Kratz AL, et al
Prevalence, co-occurrence, and trajectories of pain, fatigue, depression, and anxiety in the year following multiple sclerosis diagnosis.
Mult Scler. 2022;28:620-631.
PubMed Abstract available

March 2022

GASPERI C, Hapfelmeier A, Schneider A, Kuhn KA, et al
Association of pregnancies with risk of multiple sclerosis.
Mult Scler. 2022 Mar 18:13524585221080542. doi: 10.1177/13524585221080542.
PubMed Abstract available

PORTACCIO E, Pasto L, Razzolini L, Moiola L, et al
Natalizumab treatment and pregnancy in multiple sclerosis: A reappraisal of maternal and infant outcomes after 6 years.
Mult Scler. 2022 Mar 16:13524585221079598. doi: 10.1177/13524585221079598.
PubMed Abstract available

RIEMENSCHNEIDER M, Hvid LG, Ringgaard S, Nygaard MKE, et al
Investigating the potential disease-modifying and neuroprotective efficacy of exercise therapy early in the disease course of multiple sclerosis: The Early Multiple Sclerosis Exercise Study (EMSES).
Mult Scler. 2022 Mar 16:13524585221079200. doi: 10.1177/13524585221079200.
PubMed Abstract available

CARLSON A, McGinley MP
Healthcare utilization in multiple sclerosis: Impact of disease modifying therapies and comorbidities.
Mult Scler. 2022 Mar 16:13524585221081985. doi: 10.1177/13524585221081985.
PubMed

LIANG G, Zhu F, Mirza AI, Bar-Or A, et al
Stability of the gut microbiota in persons with paediatric-onset multiple sclerosis and related demyelinating diseases.
Mult Scler. 2022 Mar 16:13524585221079533. doi: 10.1177/13524585221079533.
PubMed Abstract available

JACOBS BM, Watson C, Marshall C, Noyce A, et al
No evidence for association between polygenic risk of multiple sclerosis and MRI phenotypes in ~30,000 healthy adult UK Biobank participants.
Mult Scler. 2022 Mar 16:13524585221075744. doi: 10.1177/13524585221075744.
PubMed

DALGAS U, Stenager E, Hvid LG
Physical exercise in multiple sclerosis is not just a symptomatic therapy, it has a disease-modifying effect: Commentary.
Mult Scler. 2022 Mar 16:13524585211072702. doi: 10.1177/13524585211072702.
PubMed

MOTL RW, Sandroff BM
Physical exercise in multiple sclerosis is not just a symptomatic therapy: It has a disease-modifying effect-Yes.
Mult Scler. 2022 Mar 16:13524585211061651. doi: 10.1177/13524585211061651.
PubMed

HEESEN C, Rosenkranz SC
Physical exercise in multiple sclerosis is not just a symptomatic therapy, it has a disease-modifying effect: No.
Mult Scler. 2022 Mar 16:13524585211064968. doi: 10.1177/13524585211064968.
PubMed

WENDEL EM, Bertolini A, Kousoulos L, Rauchenzauner M, et al
Serum neurofilament light-chain levels in children with monophasic myelin oligodendrocyte glycoprotein-associated disease, multiple sclerosis, and other acquired demyelinating syndrome.
Mult Scler. 2022 Mar 14:13524585221081090. doi: 10.1177/13524585221081090.
PubMed Abstract available

BSTEH G, Hegen H, Berek K, Altmann P, et al
Olfactory threshold predicts treatment response in relapsing multiple sclerosis.
Mult Scler. 2022 Mar 12:13524585221079744. doi: 10.1177/13524585221079744.
PubMed Abstract available

DE MOL CL, Neuteboom RF, Jansen PR, White T, et al
Response: No evidence for association between polygenic risk for multiple sclerosis and MRI phenotypes in approximately 30,000 healthy adult UK Biobank participants.
Mult Scler. 2022 Mar 12:13524585221079044. doi: 10.1177/13524585221079044.
PubMed

GARTNER J, Hauser SL, Bar-Or A, Montalban X, et al
Efficacy and safety of ofatumumab in recently diagnosed, treatment-naive patients with multiple sclerosis: Results from ASCLEPIOS I and II.
Mult Scler. 2022 Mar 10:13524585221078825. doi: 10.1177/13524585221078825.
PubMed Abstract available

ARNOLD DL, Piani-Meier D, Bar-Or A, Benedict RH, et al
Effect of siponimod on magnetic resonance imaging measures of neurodegeneration and myelination in secondary progressive multiple sclerosis: Gray matter atrophy and magnetization transfer ratio analyses from the EXPAND phase 3 trial.
Mult Scler. 2022 Mar 9:13524585221076717. doi: 10.1177/13524585221076717.
PubMed Abstract available

BEBO BF JR, Allegretta M, Landsman D, Zackowski KM, et al
Pathways to cures for multiple sclerosis: A research roadmap.
Mult Scler. 2022;28:331-345.
PubMed Abstract available

HAUSER SL, Cross AH, Winthrop K, Wiendl H, et al
Safety experience with continued exposure to ofatumumab in patients with relapsing forms of multiple sclerosis for up to 3.5 years.
Mult Scler. 2022 Mar 1:13524585221079731. doi: 10.1177/13524585221079731.
PubMed Abstract available

PORTACCIO E, Tudisco L, Pasto L, Razzolini L, et al
Pregnancy in multiple sclerosis women with relapses in the year before conception increases the risk of long-term disability worsening.
Mult Scler. 2022;28:472-479.
PubMed Abstract available

VAVASOUR IM, Sun P, Graf C, Yik JT, et al
Characterization of multiple sclerosis neuroinflammation and neurodegeneration with relaxation and diffusion basis spectrum imaging.
Mult Scler. 2022;28:418-428.
PubMed Abstract available

February 2022

TUR C, Dubessy AL, Otero-Romero S, Amato MP, et al
The risk of infections for multiple sclerosis and neuromyelitis optica spectrum disorder disease-modifying treatments: Eighth European Committee for Treatment and Research in Multiple Sclerosis Focused Workshop Review. April 2021.
Mult Scler. 2022 Feb 23:13524585211069068. doi: 10.1177/13524585211069068.
PubMed Abstract available

SHAFIN N, Ismail CAN, Mustafa MZ, Ghani N, et al
Thematic analysis of multiple sclerosis research by enhanced strategic diagram.
Mult Scler. 2022 Feb 15:13524585221075542. doi: 10.1177/13524585221075542.
PubMed Abstract available

Erratum to "Assessing diagnosis disclosure and concealment in multiple sclerosis: building a framework for moving forward".
Mult Scler. 2022 Feb 11:13524585221079450. doi: 10.1177/13524585221079450.
PubMed

BECK ES, Maranzano J, Luciano NJ, Parvathaneni P, et al
Cortical lesion hotspots and association of subpial lesions with disability in multiple sclerosis.
Mult Scler. 2022 Feb 10:13524585211069167. doi: 10.1177/13524585211069167.
PubMed Abstract available

RODRIGUEZ LLORIAN E, Zhang W, Khakban A, Patten S, et al
Productivity loss among people with early multiple sclerosis: A Canadian study.
Mult Scler. 2022 Feb 9:13524585211069070. doi: 10.1177/13524585211069070.
PubMed Abstract available

O'MAHONY J, Banwell B, Laporte A, Brown A, et al
The health-related quality of life of children with multiple sclerosis is mediated by the health-related quality of life of their parents.
Mult Scler. 2022 Feb 7:13524585211061521. doi: 10.1177/13524585211061521.
PubMed Abstract available

HOLM HANSEN R, Hojsgaard Chow H, Talbot J, Buhelt S, et al
Peripheral helper T cells in the pathogenesis of multiple sclerosis.
Mult Scler. 2022 Feb 3:13524585211067696. doi: 10.1177/13524585211067696.
PubMed Abstract available

DOBSON R, Chung K
Natalizumab concentrations during pregnancy in three patients with multiple sclerosis: A clinical commentary.
Mult Scler. 2022;28:326-327.
PubMed

COYLE PK, Syritsyna O
DMTs should be trialed in individuals with PPMS and SPMS with or without recent disease activity - Yes.
Mult Scler. 2022;28:183-185.
PubMed

BERMEL RA
DMTs should be trialed in individuals with PPMS and SPMS with or without recent disease activity - No.
Mult Scler. 2022;28:185-187.
PubMed

FOX RJ, Tintore M
DMTs should be trialed in individuals with PPMS and SPMS with or without recent disease activity - Commentary.
Mult Scler. 2022;28:187-188.
PubMed

HILLERT J, Tsai JA, Nouhi M, Glaser A, et al
A comparative study of teriflunomide and dimethyl fumarate within the Swedish MS Registry.
Mult Scler. 2022;28:237-246.
PubMed Abstract available

ZHENG Y, Dudman J, Chen JT, Mahajan KR, et al
Sensitivity of T1/T2-weighted ratio in detection of cortical demyelination is similar to magnetization transfer ratio using post-mortem MRI.
Mult Scler. 2022;28:198-205.
PubMed Abstract available

PFEUFFER S, Rolfes L, Hackert J, Kleinschnitz K, et al
Effectiveness and safety of cladribine in MS: Real-world experience from two tertiary centres.
Mult Scler. 2022;28:257-268.
PubMed Abstract available

January 2022

LIAO CM, Kuo WY, Kung PT, Chuan CH, et al
Epidemiological investigation of multiple sclerosis and related medical utilisation in Taiwan.
Mult Scler. 2022 Jan 25:13524585211061341. doi: 10.1177/13524585211061341.
PubMed Abstract available

NAKAMURA K, Zheng Y, Ontaneda D
T1/T2-weighted ratio is a surrogate marker of demyelination in multiple sclerosis-yes.
Mult Scler. 2022 Jan 22:13524585211066313. doi: 10.1177/13524585211066313.
PubMed

MUHLAU M
T1/T2-weighted ratio is a surrogate marker of demyelination in multiple sclerosis: No.
Mult Scler. 2022 Jan 22:13524585211063622. doi: 10.1177/13524585211063622.
PubMed

ROVIRA A, Pareto D
T1/T2-weighted ratio is a surrogate marker of demyelination in multiple sclerosis - Commentary.
Mult Scler. 2022 Jan 22:13524585211069363. doi: 10.1177/13524585211069363.
PubMed

KEVER A, Riley CS, Leavitt VM
Diagnosis concealment is associated with psychosocial outcomes in persons with multiple sclerosis.
Mult Scler. 2022 Jan 16:13524585211070496. doi: 10.1177/13524585211070496.
PubMed Abstract available

P MOSS B, Miller DM
Assessing diagnosis disclosure and concealment in multiple sclerosis: Building a framework for moving forward.
Mult Scler. 2022 Jan 11:13524585211069668. doi: 10.1177/13524585211069668.
PubMed

BELVISI D, Canevelli M, Marfia GA, Ferraro E, et al
Response to "Frailty in multiple sclerosis: A closer look at the deficit accumulation framework".
Mult Scler. 2022 Jan 8:13524585211068150. doi: 10.1177/13524585211068150.
PubMed

ZIAEI A, Lavery AM, Shao XM, Adams C, et al
Gene-environment interactions increase the risk of pediatric-onset multiple sclerosis associated with ozone pollution.
Mult Scler. 2022 Jan 8:13524585211069926. doi: 10.1177/13524585211069926.
PubMed Abstract available

VAN KEMPEN ZL, Hogenboom L, Killestein J
Stable multiple sclerosis patients on anti-CD20 therapy should go on extended interval dosing: NO.
Mult Scler. 2022 Jan 7:13524585211064441. doi: 10.1177/13524585211064441.
PubMed

COHEN JA, Bermel RA, Grossman CI, Hersh CM, et al
Immunoglobulin G immune response to SARS-CoV-2 vaccination in people living with multiple sclerosis within Multiple Sclerosis Partners Advancing Technology and Health Solutions.
Mult Scler. 2022 Jan 7:13524585211061343. doi: 10.1177/13524585211061343.
PubMed Abstract available

THOMPSON AJ, Carroll W, Ciccarelli O, Comi G, et al
Charting a global research strategy for progressive MS-An international progressive MS Alliance proposal.
Mult Scler. 2022;28:16-28.
PubMed Abstract available

COMABELLA M, Clarke MA, Schaedelin S, Tintore M, et al
CSF chitinase 3-like 1 is associated with iron rims in patients with a first demyelinating event.
Mult Scler. 2022;28:71-81.
PubMed Abstract available

SIGNORIELLO E, Lus G, Bonavita S, Lanzillo R, et al
Switch from sequestering to anti-CD20 depleting treatment: disease activity outcomes during wash-out and in the first 6 months of ocrelizumab therapy.
Mult Scler. 2022;28:93-101.
PubMed Abstract available

December 2021

GAITAN MI, Sanchez M, Farez MF, Fiol MP, et al
The frequency and characteristics of multiple sclerosis misdiagnosis in Latin America: A referral center study in Buenos Aires, Argentina.
Mult Scler. 2021 Dec 31:13524585211067521. doi: 10.1177/13524585211067521.
PubMed Abstract available

BERNARDI G, Biagioli T, Malpassi P, De Michele T, et al
The contribute of cerebrospinal fluid free light-chain assay in the diagnosis of multiple sclerosis and other neurological diseases in an Italian multicenter study.
Mult Scler. 2021 Dec 30:13524585211064121. doi: 10.1177/13524585211064121.
PubMed Abstract available

CAVACO S, Ferreira I, Moreira I, Santos E, et al
Cognitive dysfunction and mortality in multiple sclerosis: Long-term retrospective review.
Mult Scler. 2021 Dec 30:13524585211066598. doi: 10.1177/13524585211066598.
PubMed Abstract available

VAN KEMPEN ZL, Toorop AA, Sellebjerg F, Giovannoni G, et al
Extended dosing of monoclonal antibodies in multiple sclerosis.
Mult Scler. 2021 Dec 24:13524585211065711. doi: 10.1177/13524585211065711.
PubMed Abstract available

NG HS, Zhu F, Kingwell E, Zhao Y, et al
Disease-modifying drugs for multiple sclerosis and subsequent health service use.
Mult Scler. 2021 Dec 24:13524585211063403. doi: 10.1177/13524585211063403.
PubMed Abstract available

FERNANDEZ RS, Crivelli L, Pedreira ME, Allegri RF, et al
Computational basis of decision-making impairment in multiple sclerosis.
Mult Scler. 2021 Dec 21:13524585211059308. doi: 10.1177/13524585211059308.
PubMed Abstract available

ZANOTTO T, Lynch SG, Hausdorff JM, Sosnoff JJ, et al
Frailty in multiple sclerosis: A closer look at the deficit accumulation framework.
Mult Scler. 2021 Dec 21:13524585211061332. doi: 10.1177/13524585211061332.
PubMed

ROLFES L, Meuth SG
Stable multiple sclerosis patients on anti-CD20 therapy should go on extended interval dosing-"Yes".
Mult Scler. 2021 Dec 21:13524585211055593. doi: 10.1177/13524585211055593.
PubMed

TOOROP AA, Rispens T, Strijbis EM, van Oosten BW, et al
Natalizumab concentrations during pregnancy in three patients with multiple sclerosis.
Mult Scler. 2021 Dec 21:13524585211052168. doi: 10.1177/13524585211052168.
PubMed Abstract available

JANUEL E, De Seze J, Vermersch P, Maillart E, et al
Post-vaccine COVID-19 in patients with multiple sclerosis or neuromyelitis optica.
Mult Scler. 2021 Dec 21:13524585211049737. doi: 10.1177/13524585211049737.
PubMed Abstract available

COLES AJ, Jones JL, Vermersch P, Traboulsee A, et al
Autoimmunity and long-term safety and efficacy of alemtuzumab for multiple sclerosis: Benefit/risk following review of trial and post-marketing data.
Mult Scler. 2021 Dec 9:13524585211061335. doi: 10.1177/13524585211061335.
PubMed Abstract available

ROVIRA A, Corral JF, Auger C, Valverde S, et al
Assessment of automatic decision-support systems for detecting active T2 lesions in multiple sclerosis patients.
Mult Scler. 2021 Dec 3:13524585211061339. doi: 10.1177/13524585211061339.
PubMed Abstract available

LEEKOFF M, Culpepper W, Jin S, Lee-Wilk T, et al
Impact of comorbid post traumatic stress disorder on multiple sclerosis in military veterans: A population-based cohort study.
Mult Scler. 2021 Dec 2:13524585211058361. doi: 10.1177/13524585211058361.
PubMed Abstract available

NOURBAKHSH B
Serious side effects of amantadine: Rethinking the benefits and risks of medications for MS fatigue.
Mult Scler. 2021;27:2290.
PubMed

LEHMANN H, Zveik O, Levin N, Brill L, et al
Brain MRI activity during the year before pregnancy can predict post-partum clinical relapses.
Mult Scler. 2021;27:2232-2239.
PubMed Abstract available

OH J, Suthiphosuwan S, Sati P, Absinta M, et al
Cognitive impairment, the central vein sign, and paramagnetic rim lesions in RIS.
Mult Scler. 2021;27:2199-2208.
PubMed Abstract available

November 2021

SARKAR P, Redondo J, Hares K, Bailey S, et al
Reduced expression of mitochondrial fumarate hydratase in progressive multiple sclerosis contributes to impaired in vitro mesenchymal stromal cell-mediated neuroprotection.
Mult Scler. 2021 Nov 29:13524585211060686. doi: 10.1177/13524585211060686.
PubMed Abstract available

OTERO-ROMERO S, Carbonell-Mirabent P, Midaglia L, Zuluaga M, et al
Oral contraceptives do not modify the risk of a second attack and disability accrual in a prospective cohort of women with a clinically isolated syndrome and early multiple sclerosis.
Mult Scler. 2021 Nov 29:13524585211053001. doi: 10.1177/13524585211053001.
PubMed Abstract available

KIRA JI, Nakahara J, Sazonov DV, Kurosawa T, et al
Effect of ofatumumab versus placebo in relapsing multiple sclerosis patients from Japan and Russia: Phase 2 APOLITOS study.
Mult Scler. 2021 Nov 17:13524585211055934. doi: 10.1177/13524585211055934.
PubMed Abstract available

SCHORR EM, Kurz D, Rossi KC, Zhang M, et al
Depression readmission risk is elevated in multiple sclerosis compared to other chronic illnesses.
Mult Scler. 2021 Nov 17:13524585211051316. doi: 10.1177/13524585211051316.
PubMed Abstract available

MARRIE RA, McKay K
Administrative data for observational research in multiple sclerosis: Opportunities and challenges.
Mult Scler. 2021 Nov 17:13524585211055787. doi: 10.1177/13524585211055787.
PubMed

MAUBEUGE N, Deloire MS, Brochet B, Charre-Morin J, et al
Validation of a Brief Computerized Cognitive Assessment in Multiple Sclerosis (BCCAMS) and comparison with reference batteries.
Mult Scler. 2021 Nov 12:13524585211054006. doi: 10.1177/13524585211054006.
PubMed Abstract available

MOUMDJIAN L, Moens B, Van Wijmeersh B, Leman M, et al
Application of step and beat alignment approaches and its effect on gait in progressive multiple sclerosis with severe cerebellar ataxia: A proof of concept case study.
Mult Scler. 2021 Nov 2:13524585211054000. doi: 10.1177/13524585211054000.
PubMed Abstract available

DAHLKE F, Arnold DL, Aarden P, Ganjgahi H, et al
Characterisation of MS phenotypes across the age span using a novel data set integrating 34 clinical trials (NO.MS cohort): Age is a key contributor to presentation.
Mult Scler. 2021;27:2062-2076.
PubMed Abstract available

October 2021

MISICKA E, Davis MF, Kim W, Brugger SW, et al
A higher burden of multiple sclerosis genetic risk confers an earlier onset.
Mult Scler. 2021 Oct 28:13524585211053155. doi: 10.1177/13524585211053155.
PubMed Abstract available

PONCET-MEGEMONT L, Pereira B, Rollot F, Sormani MP, et al
Estimation of sample size in randomized controlled trials in multiple sclerosis studying annualized relapse rates: A systematic review.
Mult Scler. 2021 Oct 26:13524585211052400. doi: 10.1177/13524585211052400.
PubMed Abstract available

BERGAMASCHI R, Montomoli C
Air pollution is a risk factor for multiple sclerosis - Yes.
Mult Scler. 2021 Oct 22:13524585211035953. doi: 10.1177/13524585211035953.
PubMed

DELGADO-GARCIA G, Corona T
Air pollution is a risk factor for multiple sclerosis - No.
Mult Scler. 2021 Oct 22:13524585211026875. doi: 10.1177/13524585211026875.
PubMed

SAHRAIAN MA
Air pollution is a risk factor for multiple sclerosis - Commentary.
Mult Scler. 2021 Oct 22:13524585211046352. doi: 10.1177/13524585211046352.
PubMed

ZHONG M, van der Walt A, Stankovich J, Kalincik T, et al
Prediction of multiple sclerosis outcomes when switching to ocrelizumab.
Mult Scler. 2021 Oct 8:13524585211049986. doi: 10.1177/13524585211049986.
PubMed Abstract available

UHER T, Havrdova EK, Benkert P, Bergsland N, et al
Measurement of neurofilaments improves stratification of future disease activity in early multiple sclerosis.
Mult Scler. 2021 Oct 6:13524585211047977. doi: 10.1177/13524585211047977.
PubMed Abstract available

VILLOSLADA P
Personalized medicine for multiple sclerosis: How to integrate neurofilament light chain levels in the decision?
Mult Scler. 2021 Oct 6:13524585211049552. doi: 10.1177/13524585211049552.
PubMed

WEINSTOCK Z, Morrow S, Conway D, Fuchs T, et al
Interpreting change on the Symbol Digit Modalities Test in people with relapsing multiple sclerosis using the reliable change methodology.
Mult Scler. 2021 Oct 6:13524585211049397. doi: 10.1177/13524585211049397.
PubMed Abstract available

SOLOMON AJ, Kaisey M, Krieger SC, Chahin S, et al
Multiple sclerosis diagnosis: Knowledge gaps and opportunities for educational intervention in neurologists in the United States.
Mult Scler. 2021 Oct 6:13524585211048401. doi: 10.1177/13524585211048401.
PubMed Abstract available

BOSMA AR, Murley C, Aspling J, Hillert J, et al
Trajectories of sickness absence and disability pension days among people with multiple sclerosis by type of occupation.
Mult Scler. 2021 Oct 6:13524585211048759. doi: 10.1177/13524585211048759.
PubMed Abstract available

BAR-OR A, Wiendl H, Montalban X, Alvarez E, et al
Rapid and sustained B-cell depletion with subcutaneous ofatumumab in relapsing multiple sclerosis: APLIOS, a randomized phase-2 study.
Mult Scler. 2021 Oct 4:13524585211044479. doi: 10.1177/13524585211044479.
PubMed Abstract available

GROTHE M, Ellenberger D, von Podewils F, Stahmann A, et al
Epilepsy as a predictor of disease progression in multiple sclerosis.
Mult Scler. 2021 Oct 1:13524585211046739. doi: 10.1177/13524585211046739.
PubMed Abstract available

SANDROFF BM, Motl RW, Amato MP, Brichetto G, et al
Cardiorespiratory fitness and free-living physical activity are not associated with cognition in persons with progressive multiple sclerosis: Baseline analyses from the CogEx study.
Mult Scler. 2021 Oct 1:13524585211048397. doi: 10.1177/13524585211048397.
PubMed Abstract available

BSTEH G, Durauer S, Assar H, Hegen H, et al
Humoral immune response after COVID-19 in multiple sclerosis: A nation-wide Austrian study.
Mult Scler. 2021 Oct 1:13524585211049391. doi: 10.1177/13524585211049391.
PubMed Abstract available

GEORGIEVA ZG, Dffinger R, Kumararatne D, Coles AJ, et al
Diminished seroconversion following a single SARS-COV-2 vaccine in ocrelizumab-treated relapsing-remitting multiple sclerosis patients.
Mult Scler. 2021 Oct 1:13524585211046786. doi: 10.1177/13524585211046786.
PubMed Abstract available

CAMERON MH, Hildebrand A, Hugos CL, Judd GI, et al
Free From Falls education and exercise program for reducing falls in people with multiple sclerosis: A randomized controlled trial.
Mult Scler. 2021 Oct 1:13524585211046898. doi: 10.1177/13524585211046898.
PubMed Abstract available

ROBERS MV, Chan C, Vajdi B, Chiong-Rivero H, et al
Hypertension and hypertension severity in Hispanics/Latinx with MS.
Mult Scler. 2021;27:1894-1901.
PubMed Abstract available

ELKJAER ML, Frisch T, Tonazzolli A, Rottger R, et al
Unbiased examination of genome-wide human endogenous retrovirus transcripts in MS brain lesions.
Mult Scler. 2021;27:1829-1837.
PubMed Abstract available

KOCH MW, Mostert JP, Uitdehaag B, Cutter G, et al
A comparison of clinical outcomes in PPMS in the INFORMS original trial data set.
Mult Scler. 2021;27:1864-1874.
PubMed Abstract available

KOCH MW, Metz L, Cutter G
An enrichment strategy for clinical trials in SPMS.
Mult Scler. 2021;27:1884-1893.
PubMed Abstract available

September 2021

BUSSAS M, Grahl S, Pongratz V, Berthele A, et al
Gray matter atrophy in relapsing-remitting multiple sclerosis is associated with white matter lesions in connecting fibers.
Mult Scler. 2021 Sep 30:13524585211044957. doi: 10.1177/13524585211044957.
PubMed Abstract available

KEVER A, Leavitt VM
Assessing diagnosis disclosure and concealment in multiple sclerosis: Development and initial validation of the DISCO-MS survey.
Mult Scler. 2021 Sep 9:13524585211037581. doi: 10.1177/13524585211037581.
PubMed Abstract available

KRYSKO KM, Anderson A, Singh J, McPolin K, et al
Risk factors for peripartum depression in women with multiple sclerosis.
Mult Scler. 2021 Sep 9:13524585211041108. doi: 10.1177/13524585211041108.
PubMed Abstract available

WOJCIK C, Jaworski M 3rd, Dwyer MG, Youngs M, et al
Benchmarks of meaningful improvement on neurocognitive tests in multiple sclerosis.
Mult Scler. 2021 Sep 9:13524585211044672. doi: 10.1177/13524585211044672.
PubMed Abstract available

TREMLETT H, Okuda DT, Lebrun-Frenay C
The multiple sclerosis prodrome is just unspecific symptoms in radiologically isolated syndrome patients - No.
Mult Scler. 2021 Sep 8:13524585211035951. doi: 10.1177/13524585211035951.
PubMed

GNANAPAVAN S
The multiple sclerosis prodrome is just unspecific symptoms in radiologically isolated syndrome patients - Yes.
Mult Scler. 2021 Sep 8:13524585211040223. doi: 10.1177/13524585211040223.
PubMed

MAKHANI N
The multiple sclerosis prodrome is just unspecific symptoms in radiologically isolated syndrome patients - Commentary.
Mult Scler. 2021 Sep 8:13524585211044951. doi: 10.1177/13524585211044951.
PubMed

BRADLEY L
Delayed amantadine toxicity causing apparent progression of multiple sclerosis.
Mult Scler. 2021 Sep 5:13524585211035737. doi: 10.1177/13524585211035737.
PubMed Abstract available

ENZINGER C
Slowly expanding lesions are a marker of progressive multiple sclerosis - Commentary.
Mult Scler. 2021 Sep 3:13524585211040225. doi: 10.1177/13524585211040225.
PubMed

HARTUNG HP, Meuth SG, Thompson AJ
Paradigm shifts: Early initiation of high-efficacy disease-modifying treatment in multiple sclerosis.
Mult Scler. 2021;27:1473-1476.
PubMed

GOLD R, Arnold DL, Bar-Or A, Fox RJ, et al
Long-term safety and efficacy of dimethyl fumarate for up to 13 years in patients with relapsing-remitting multiple sclerosis: Final ENDORSE study results.
Mult Scler. 2021 Sep 1:13524585211037909. doi: 10.1177/13524585211037909.
PubMed Abstract available

August 2021

CONWAY DS, Marck CH
Comorbidities require special attention in minorities with multiple sclerosis.
Mult Scler. 2021 Aug 27:13524585211037578. doi: 10.1177/13524585211037578.
PubMed

BLASCHKE SJ, Ellenberger D, Flachenecker P, Hellwig K, et al
Time to diagnosis in multiple sclerosis: Epidemiological data from the German Multiple Sclerosis Registry.
Mult Scler. 2021 Aug 27:13524585211039753. doi: 10.1177/13524585211039753.
PubMed Abstract available

COHEN JA, Cameron MH, Goldman MD, Goodman AD, et al
A Phase 3, double-blind, placebo-controlled efficacy and safety study of ADS-5102 (Amantadine) extended-release capsules in people with multiple sclerosis and walking impairment.
Mult Scler. 2021 Aug 27:13524585211035333. doi: 10.1177/13524585211035333.
PubMed Abstract available

GUERRA T, Bollo L, Trojano M, Iaffaldano P, et al
Dengue fever in a multiple sclerosis patient taking Ocrelizumab.
Mult Scler. 2021 Aug 27:13524585211030214. doi: 10.1177/13524585211030214.
PubMed Abstract available

ALONSO R, Galleguillos L
Dengue fever in a multiple sclerosis patient taking ocrelizumab: Clinical commentary.
Mult Scler. 2021 Aug 27:13524585211039750. doi: 10.1177/13524585211039750.
PubMed

ABBADESSA G, Lavorgna L, Treaba CA, Bonavita S, et al
Hemostatic factors in the pathogenesis of neuroinflammation in multiple sclerosis.
Mult Scler. 2021 Aug 19:13524585211039111. doi: 10.1177/13524585211039111.
PubMed Abstract available

BUTLER PAGNOTTI R, Hua LH, Miller JB
Cognition and disease characteristics in adult onset versus late onset multiple sclerosis.
Mult Scler. 2021 Aug 19:13524585211039112. doi: 10.1177/13524585211039112.
PubMed Abstract available

TILLAUT H, Degremont A, Kerbrat S, Roux J, et al
Pregnancy in women with multiple sclerosis in France from 2010 to 2015: Incidence, outcomes, and exposure to disease-modifying therapies.
Mult Scler. 2021 Aug 19:13524585211035376. doi: 10.1177/13524585211035376.
PubMed Abstract available

ROMMER PS, Bsteh G, Berger T, Zettl UK, et al
SARS-CoV-2 antibodies in multiple sclerosis patients depending on the vaccine mode of action?
Mult Scler. 2021 Aug 13:13524585211039128. doi: 10.1177/13524585211039128.
PubMed

MARCHESI O, Bonacchi R, Valsasina P, Preziosa P, et al
Functional and structural MRI correlates of executive functions in multiple sclerosis.
Mult Scler. 2021 Aug 13:13524585211033184. doi: 10.1177/13524585211033184.
PubMed Abstract available

CLAFLIN SB, Campbell JA, Mason DF, Kalincik T, et al
The effect of national disease-modifying therapy subsidy policy on long-term disability outcomes in people with multiple sclerosis.
Mult Scler. 2021 Aug 13:13524585211035948. doi: 10.1177/13524585211035948.
PubMed Abstract available

WEINSTOCK-GUTTMAN B, Bermel R, Cutter G, Freedman MS, et al
Ocrelizumab treatment for relapsing-remitting multiple sclerosis after a suboptimal response to previous disease-modifying therapy: A nonrandomized controlled trial.
Mult Scler. 2021 Aug 12:13524585211035740. doi: 10.1177/13524585211035740.
PubMed Abstract available

DE MOL CL, Neuteboom RF, Jansen PR, White T, et al
White matter microstructural differences in children and genetic risk for multiple sclerosis: A population-based study.
Mult Scler. 2021 Aug 11:13524585211034826. doi: 10.1177/13524585211034826.
PubMed Abstract available

AYADI N, Oertel FC, Asseyer S, Rust R, et al
Impaired motion perception is associated with functional and structural visual pathway damage in multiple sclerosis and neuromyelitis optica spectrum disorders.
Mult Scler. 2021 Aug 11:13524585211032801. doi: 10.1177/13524585211032801.
PubMed Abstract available

ZHENG F, Li Y, Zhuo Z, Duan Y, et al
Structural and functional hippocampal alterations in Multiple sclerosis and neuromyelitis optica spectrum disorder.
Mult Scler. 2021 Aug 11:13524585211032800. doi: 10.1177/13524585211032800.
PubMed Abstract available

COMI G, Dadon Y, Sasson N, Steinerman JR, et al
CONCERTO: A randomized, placebo-controlled trial of oral laquinimod in relapsing-remitting multiple sclerosis.
Mult Scler. 2021 Aug 11:13524585211032803. doi: 10.1177/13524585211032803.
PubMed Abstract available

PANDIT L
Fair and equitable treatment for multiple sclerosis in resource-poor regions: The need for off-label therapies and regional treatment guidelines.
Mult Scler. 2021;27:1320-1322.
PubMed

KANINIA S, Grammatikos A, Urankar K, Renowden SA, et al
CNS demyelination associated with immune dysregulation and a novel CTLA-4 variant.
Mult Scler. 2021;27:1464-1467.
PubMed Abstract available

July 2021

SORMANI MP, Schiavetti I, Landi D, Carmisciano L, et al
SARS-CoV-2 serology after COVID-19 in multiple sclerosis: An international cohort study.
Mult Scler. 2021 Jul 30:13524585211035318. doi: 10.1177/13524585211035318.
PubMed Abstract available

ROTSTEIN D, Maxwell C, Tu K, Gatley J, et al
High prevalence of comorbidities at diagnosis in immigrants with multiple sclerosis.
Mult Scler. 2021 Jul 30:13524585211031791. doi: 10.1177/13524585211031791.
PubMed Abstract available

PITTERI M, Magliozzi R, Nicholas R, Ziccardi S, et al
Cerebrospinal fluid inflammatory profile of cognitive impairment in newly diagnosed multiple sclerosis patients.
Mult Scler. 2021 Jul 30:13524585211032510. doi: 10.1177/13524585211032510.
PubMed Abstract available

UHR L, Mateen FJ
COVID-19 vaccine hesitancy in multiple sclerosis: A cross-sectional survey.
Mult Scler. 2021 Jul 27:13524585211030647. doi: 10.1177/13524585211030647.
PubMed Abstract available

LAURSON-DOUBE J, Rijke N, Helme A, Baneke P, et al
Ethical use of off-label disease-modifying therapies for multiple sclerosis.
Mult Scler. 2021 Jul 26:13524585211030207. doi: 10.1177/13524585211030207.
PubMed Abstract available

KOCH MW, Mostert J, Repovic P, Bowen JD, et al
MRI brain volume loss, lesion burden, and clinical outcome in secondary progressive multiple sclerosis.
Mult Scler. 2021 Jul 26:13524585211031801. doi: 10.1177/13524585211031801.
PubMed Abstract available

LONGINETTI E, Frisell T, Englund S, Reutfors J, et al
Risk of depression in multiple sclerosis across disease-modifying therapies.
Mult Scler. 2021 Jul 15:13524585211031128. doi: 10.1177/13524585211031128.
PubMed Abstract available

BOUMAN PM, Strijbis VI, Jonkman LE, Hulst HE, et al
Artificial double inversion recovery images for (juxta)cortical lesion visualization in multiple sclerosis.
Mult Scler. 2021 Jul 14:13524585211029860. doi: 10.1177/13524585211029860.
PubMed Abstract available

MONTALBAN X, Graves J, Midaglia L, Mulero P, et al
A smartphone sensor-based digital outcome assessment of multiple sclerosis.
Mult Scler. 2021 Jul 14:13524585211028561. doi: 10.1177/13524585211028561.
PubMed Abstract available

HOGESTOL EA, Ghezzo S, Nygaard GO, Espeseth T, et al
Functional connectivity in multiple sclerosis modelled as connectome stability: A 5-year follow-up study.
Mult Scler. 2021 Jul 14:13524585211030212. doi: 10.1177/13524585211030212.
PubMed Abstract available

WIJERATNE T, Carroll W
World Brain Day 2021: Global campaign to stop multiple sclerosis.
Mult Scler. 2021 Jul 14:13524585211030147. doi: 10.1177/13524585211030147.
PubMed

HARTUNG HP, Derfuss T, Cree BA, Sormani MP, et al
Efficacy and safety of temelimab in multiple sclerosis: Results of a randomized phase 2b and extension study.
Mult Scler. 2021 Jul 9:13524585211024997. doi: 10.1177/13524585211024997.
PubMed Abstract available

VAN LIEROP ZY, Toorop AA, van Ballegoij WJ, Olde Dubbelink TB, et al
Personalized B-cell tailored dosing of ocrelizumab in patients with multiple sclerosis during the COVID-19 pandemic.
Mult Scler. 2021 Jul 9:13524585211028833. doi: 10.1177/13524585211028833.
PubMed Abstract available

SPELMAN T, Forsberg L, McKay K, Glaser A, et al
Increased rate of hospitalisation for COVID-19 among rituximab-treated multiple sclerosis patients: A study of the Swedish multiple sclerosis registry.
Mult Scler. 2021 Jul 2:13524585211026272. doi: 10.1177/13524585211026272.
PubMed Abstract available

KALINOWSKA-LYSZCZARZ A, Tillema JM, Tobin WO, Guo Y, et al
Long-term clinical, MRI, and cognitive follow-up in a large cohort of pathologically confirmed, predominantly tumefactive multiple sclerosis.
Mult Scler. 2021 Jul 2:13524585211024162. doi: 10.1177/13524585211024162.
PubMed Abstract available

NAUTA IM, Bertens D, van Dam M, Huiskamp M, et al
Performance validity in outpatients with multiple sclerosis and cognitive complaints.
Mult Scler. 2021 Jul 2:13524585211025780. doi: 10.1177/13524585211025780.
PubMed Abstract available

ESHAGHI A
Towards an objective classification of multiple sclerosis.
Mult Scler. 2021;27:1151-1152.
PubMed

CALDITO NG, O'Leary S, Stuve O
Persistent severe lymphopenia 5 years after dimethyl fumarate discontinuation.
Mult Scler. 2021;27:1306-1308.
PubMed Abstract available

MARRIE RA, Patel R, Bernstein CN, Bolton JM, et al
Anxiety and depression affect performance on the symbol digit modalities test over time in MS and other immune disorders.
Mult Scler. 2021;27:1284-1292.
PubMed Abstract available

CENCIONI MT, Ali R, Nicholas R, Muraro PA, et al
Defective CD19+CD24(hi)CD38(hi) transitional B-cell function in patients with relapsing-remitting MS.
Mult Scler. 2021;27:1187-1197.
PubMed Abstract available

June 2021

SCHONFELDER K, Schuh H, Pfister F, Kramer J, et al
Autoimmune glomerulonephritis in a multiple sclerosis patient after cladribine treatment.
Mult Scler. 2021 Jun 24:13524585211022719. doi: 10.1177/13524585211022719.
PubMed Abstract available

MIZELL R, Chen H, Lambe J, Saidha S, et al
Association of retinal atrophy with cortical lesions and leptomeningeal enhancement in multiple sclerosis on 7T MRI.
Mult Scler. 2021 Jun 14:13524585211023343. doi: 10.1177/13524585211023343.
PubMed Abstract available

BOMMARITO G, Tarun A, Farouj Y, Preti MG, et al
Altered anterior default mode network dynamics in progressive multiple sclerosis.
Mult Scler. 2021 Jun 14:13524585211018116. doi: 10.1177/13524585211018116.
PubMed Abstract available

HIDALGO DE LA CRUZ M, Valsasina P, Meani A, Gallo A, et al
Differential association of cortical, subcortical and spinal cord damage with multiple sclerosis disability milestones: A multiparametric MRI study.
Mult Scler. 2021 Jun 14:13524585211020296. doi: 10.1177/13524585211020296.
PubMed Abstract available

WU J, Engdahl E, Gustafsson R, Fogdell-Hahn A, et al
High antibody levels against human herpesvirus-6A interact with lifestyle factors in multiple sclerosis development.
Mult Scler. 2021 Jun 14:13524585211022011. doi: 10.1177/13524585211022011.
PubMed Abstract available

VERCELLINO M, Marasciulo S, Grifoni S, Vallino-Costassa E, et al
Acute and chronic synaptic pathology in multiple sclerosis gray matter.
Mult Scler. 2021 Jun 14:13524585211022174. doi: 10.1177/13524585211022174.
PubMed Abstract available

CORTESE R, Battaglini M, Parodi F, Stromillo ML, et al
Mild gray matter atrophy in patients with long-standing multiple sclerosis and favorable clinical course.
Mult Scler. 2021 Jun 8:13524585211019650. doi: 10.1177/13524585211019650.
PubMed Abstract available

SADOVNICK AD, Yee IM, Criscuoli M, DeLuca GC, et al
Genes and environment in multiple sclerosis: Impact of temporal changes in the sex ratio on recurrence risks.
Mult Scler. 2021 Jun 8:13524585211020221. doi: 10.1177/13524585211020221.
PubMed Abstract available

KALINOWSKI A, Cutter G, Bozinov N, Hinman JA, et al
The timed 25-foot walk in a large cohort of multiple sclerosis patients.
Mult Scler. 2021 Jun 8:13524585211017013. doi: 10.1177/13524585211017013.
PubMed Abstract available

GARJANI A, Hunter R, Law GR, Middleton RM, et al
Mental health of people with multiple sclerosis during the COVID-19 outbreak: A prospective cohort and cross-sectional case-control study of the UK MS Register.
Mult Scler. 2021 Jun 3:13524585211020435. doi: 10.1177/13524585211020435.
PubMed Abstract available

SCHMIERER K, Giovannoni G
MS can be considered a primary progressive disease in all cases, but some patients have superimposed relapses - Commentary.
Mult Scler. 2021;27:1006-1007.
PubMed

SCALFARI A
MS can be considered a primary progressive disease in all cases, but some patients have superimposed relapses - Yes.
Mult Scler. 2021;27:1002-1004.
PubMed

CROSS AH, Naismith RT
MS can be considered a primary progressive disease in all cases, but some patients have superimposed relapses - No.
Mult Scler. 2021;27:1004-1005.
PubMed

ZACKOWSKI KM, Freeman J, Brichetto G, Centonze D, et al
Prioritizing progressive MS rehabilitation research: A call from the International Progressive MS Alliance.
Mult Scler. 2021;27:989-1001.
PubMed Abstract available

MORROW SA, Conway D, Fuchs T, Wojcik C, et al
Quantifying cognition and fatigue to enhance the sensitivity of the EDSS during relapses.
Mult Scler. 2021;27:1077-1087.
PubMed Abstract available

NAYAK S, Sechi E, Flanagan EP, Messina S, et al
Inflammatory activity following motor progression due to critical CNS demyelinating lesions.
Mult Scler. 2021;27:1037-1045.
PubMed Abstract available

REDER AT
Thoracic flexion provokes circumferential dysesthesia: A symptom of thoracic cord lesions in MS.
Mult Scler. 2021;27:1008-1013.
PubMed Abstract available

May 2021

MESSINA S, Mariano R, Roca-Fernandez A, Cavey A, et al
Contrasting the brain imaging features of MOG-antibody disease, with AQP4-antibody NMOSD and multiple sclerosis.
Mult Scler. 2021 May 28:13524585211018987. doi: 10.1177/13524585211018987.
PubMed Abstract available

SINGH M, Gavidia R, Dunietz GL, Washnock-Schmid E, et al
Validation of an obstructive sleep apnea symptom inventory in persons with multiple sclerosis.
Mult Scler. 2021 May 28:13524585211013014. doi: 10.1177/13524585211013014.
PubMed Abstract available

ROUX J, Kingwell E, Zhu F, Tremlett H, et al
Care consumption of people with multiple sclerosis: A multichannel sequence analysis in a population-based setting in British Columbia, Canada.
Mult Scler. 2021 May 28:13524585211016726. doi: 10.1177/13524585211016726.
PubMed Abstract available

MCMURRAN CE
Correcting gut dysbiosis can ameliorate inflammation and promote remyelination in multiple sclerosis - No.
Mult Scler. 2021 May 28:13524585211016722. doi: 10.1177/13524585211016722.
PubMed

CALVO-BARREIRO L, Clerico M, Espejo C
Correcting gut dysbiosis can ameliorate inflammation and promote remyelination in multiple sclerosis - Yes.
Mult Scler. 2021 May 28:13524585211016723. doi: 10.1177/13524585211016723.
PubMed

HOHLFELD R
Correcting gut dysbiosis can ameliorate inflammation and promote remyelination in multiple sclerosis - Commentary.
Mult Scler. 2021 May 28:13524585211018990. doi: 10.1177/13524585211018990.
PubMed

KEVER A, Buyukturkoglu K, Levin SN, Riley CS, et al
Associations of social network structure with cognition and amygdala volume in multiple sclerosis: An exploratory investigation.
Mult Scler. 2021 May 26:13524585211018349. doi: 10.1177/13524585211018349.
PubMed Abstract available

LAM KH, van Oirschot P, den Teuling B, Hulst HE, et al
Reliability, construct and concurrent validity of a smartphone-based cognition test in multiple sclerosis.
Mult Scler. 2021 May 26:13524585211018103. doi: 10.1177/13524585211018103.
PubMed Abstract available

DE STEFANO N, Sormani MP, Giovannoni G, Rammohan K, et al
Analysis of frequency and severity of relapses in multiple sclerosis patients treated with cladribine tablets or placebo: The CLARITY and CLARITY Extension studies.
Mult Scler. 2021 May 10:13524585211010294. doi: 10.1177/13524585211010294.
PubMed Abstract available

WOJCIK C, Fuchs TA, Tran H, Dwyer MG, et al
Staging and stratifying cognitive dysfunction in multiple sclerosis.
Mult Scler. 2021 May 6:13524585211011390. doi: 10.1177/13524585211011390.
PubMed Abstract available

BROWNLEE WJ, Solomon AJ
Misdiagnosis of multiple sclerosis: Time for action.
Mult Scler. 2021;27:805-806.
PubMed

LONGBRAKE EE, Mao-Draayer Y, Cascione M, Zielinski T, et al
Dimethyl fumarate treatment shifts the immune environment toward an anti-inflammatory cell profile while maintaining protective humoral immunity.
Mult Scler. 2021;27:883-894.
PubMed Abstract available

CAI MT, Zheng Y, Shen CH, Yang F, et al
Evaluation of brain and spinal cord lesion distribution criteria at disease onset in distinguishing NMOSD from MS and MOG antibody-associated disorder.
Mult Scler. 2021;27:871-882.
PubMed Abstract available

KASSA RM, Sechi E, Flanagan EP, Kaufmann TJ, et al
Onset of progressive motor impairment in patients with critical central nervous system demyelinating lesions.
Mult Scler. 2021;27:895-902.
PubMed Abstract available

April 2021

HOLLEN C, Rice J, Park M, Yadav V, et al
Rituximab for treatment of refractory multiple sclerosis relapses during pregnancy.
Mult Scler. 2021 Apr 30:1352458521998937. doi: 10.1177/1352458521998937.
PubMed Abstract available

GUNGOR F, Tarakci E, Ozdemir-Acar Z, Soysal A, et al
The effects of supervised versus home Pilates-based core stability training on lower extremity muscle strength and postural sway in people with multiple sclerosis.
Mult Scler. 2021 Apr 28:13524585211012202. doi: 10.1177/13524585211012202.
PubMed Abstract available

VAN LIEROP ZY, Wieske L, Koel-Simmelink MJ, Chatterjee M, et al
Serum contactin-1 as a biomarker of long-term disease progression in natalizumab-treated multiple sclerosis.
Mult Scler. 2021 Apr 23:13524585211010097. doi: 10.1177/13524585211010097.
PubMed Abstract available

KHADADAH S, Kimoff RJ, Duquette P, Jobin V, et al
Effect of continuous positive airway pressure treatment of obstructive sleep apnea-hypopnea in multiple sclerosis: A randomized, double-blind, placebo-controlled trial (SAMS-PAP study).
Mult Scler. 2021 Apr 23:13524585211010390. doi: 10.1177/13524585211010390.
PubMed Abstract available

HARRISON AM, Safari R, Mercer T, Picariello F, et al
Which exercise and behavioural interventions show most promise for treating fatigue in multiple sclerosis? A network meta-analysis.
Mult Scler. 2021 Apr 20:1352458521996002. doi: 10.1177/1352458521996002.
PubMed Abstract available

ALLANACH JR, Farrell JW 3rd, Mesidor M, Karimi-Abdolrezaee S, et al
Current status of neuroprotective and neuroregenerative strategies in multiple sclerosis: A systematic review.
Mult Scler. 2021 Apr 19:13524585211008760. doi: 10.1177/13524585211008760.
PubMed Abstract available

ZHOU Y, Cuellar-Partida G, Simpson Yap S, Lin X, et al
Utilising multi-large omics data to elucidate biological mechanisms within multiple sclerosis genetic susceptibly loci.
Mult Scler. 2021 Apr 19:13524585211004422. doi: 10.1177/13524585211004422.
PubMed Abstract available

PAPEIX C, Mazoyer J, Maillart E, Bensa C, et al
Multiple sclerosis: Is there a risk of worsening after yellow fever vaccination?
Mult Scler. 2021 Apr 19:13524585211006372. doi: 10.1177/13524585211006372.
PubMed Abstract available

CHATTERTON S, Withers B, Sutton IJ, Milliken ST, et al
Pregnancy post autologous stem cell transplant with BEAM conditioning for multiple sclerosis.
Mult Scler. 2021 Apr 19:13524585211005660. doi: 10.1177/13524585211005660.
PubMed Abstract available

CIOTTI JR, Eby NS, Brier MR, Wu GF, et al
Central vein sign and other radiographic features distinguishing myelin oligodendrocyte glycoprotein antibody disease from multiple sclerosis and aquaporin-4 antibody-positive neuromyelitis optica.
Mult Scler. 2021 Apr 19:13524585211007086. doi: 10.1177/13524585211007086.
PubMed Abstract available

FLEMING KM, Coote SB, Herring MP
Home-based Pilates for symptoms of anxiety, depression and fatigue among persons with multiple sclerosis: An 8-week randomized controlled trial.
Mult Scler. 2021 Apr 19:13524585211009216. doi: 10.1177/13524585211009216.
PubMed Abstract available

SCHOONHEIM MM, Pinter D, Prouskas SE, Broeders TA, et al
Disability in multiple sclerosis is related to thalamic connectivity and cortical network atrophy.
Mult Scler. 2021 Apr 19:13524585211008743. doi: 10.1177/13524585211008743.
PubMed Abstract available

D'AMICO E, Zanghi A, Calogero AE, Patti F, et al
Male fertility in relapsing-remitting multiple sclerosis patients treated with natalizumab and ocrelizumab: A prospective case-control study.
Mult Scler. 2021 Apr 19:13524585211009208. doi: 10.1177/13524585211009208.
PubMed Abstract available

CORTESE M, Bjornevik K, Chitnis T, Ascherio A, et al
Aging with multiple sclerosis: A longitudinal study of physical function, mental health, and memory in two cohorts of US women.
Mult Scler. 2021 Apr 16:13524585211007739. doi: 10.1177/13524585211007739.
PubMed Abstract available

COOPER G, Chien C, Zimmermann H, Bellmann-Strobl J, et al
Longitudinal analysis of T1w/T2w ratio in patients with multiple sclerosis from first clinical presentation.
Mult Scler. 2021 Apr 15:13524585211003479. doi: 10.1177/13524585211003479.
PubMed Abstract available

ACHIRON A, Dolev M, Menascu S, Zohar DN, et al
COVID-19 vaccination in patients with multiple sclerosis: What we have learnt by February 2021.
Mult Scler. 2021 Apr 15:13524585211003476. doi: 10.1177/13524585211003476.
PubMed Abstract available

TROJANO M, Ramio-Torrenta L, Grimaldi LM, Lubetzki C, et al
A randomized study of natalizumab dosing regimens for relapsing-remitting multiple sclerosis.
Mult Scler. 2021 Apr 6:13524585211003020. doi: 10.1177/13524585211003020.
PubMed Abstract available

BESSING B, Honan CA, van der Mei I, Taylor BV, et al
Development and psychometric properties of the Multiple Sclerosis Knowledge Assessment Scale: Rasch analysis of a novel tool for evaluating MS knowledge.
Mult Scler. 2021;27:767-777.
PubMed Abstract available

VAN DAM M, Hulst HE, Schoonheim MM
Coupling structure and function in early MS: How a less diverse repertoire of brain function could lead to clinical progression.
Mult Scler. 2021;27:491-493.
PubMed

MANCINELLI CR, Scarpazza C, Cordioli C, De Rossi N, et al
Switching to ocrelizumab in RRMS patients at risk of PML previously treated with extended interval dosing of natalizumab.
Mult Scler. 2021;27:790-794.
PubMed Abstract available

BIGAUT K, Fabacher T, Kremer L, Ongagna JC, et al
Long-term effect of natalizumab in patients with RRMS: TYSTEN cohort.
Mult Scler. 2021;27:729-741.
PubMed Abstract available

KUNCHOK A, Lechner-Scott J, Granella F, Trojano M, et al
Prediction of on-treatment disability worsening in RRMS with the MAGNIMS score.
Mult Scler. 2021;27:695-705.
PubMed Abstract available

SECHI E, Messina S, Keegan BM, Buciuc M, et al
Critical spinal cord lesions associate with secondary progressive motor impairment in long-standing MS: A population-based case-control study.
Mult Scler. 2021;27:667-673.
PubMed Abstract available

DATTA P, Ciplea AI, Rewers-Felkins K, Baker T, et al
Cladribine transfer into human milk: A case report.
Mult Scler. 2021;27:799-801.
PubMed Abstract available

March 2021

HOWLETT-PRIETO Q, Feng X, Kramer JF, Kramer KJ, et al
Anti-CD20 therapy corrects a CD8 regulatory T cell deficit in multiple sclerosis.
Mult Scler. 2021 Mar 30:13524585211003301. doi: 10.1177/13524585211003301.
PubMed Abstract available

THEODORSDOTTIR A, Debrabant B, Magyari M, Kant M, et al
Alemtuzumab treatment in Denmark: A national study based on the Danish Multiple Sclerosis Registry.
Mult Scler. 2021 Mar 29:13524585211003291. doi: 10.1177/13524585211003291.
PubMed Abstract available

CREE BA, Cohen JA, Reder AT, Tomic D, et al
Disability improvement as a clinically relevant outcome in clinical trials of relapsing forms of multiple sclerosis.
Mult Scler. 2021 Mar 26:13524585211000280. doi: 10.1177/13524585211000280.
PubMed Abstract available

PORTACCIO E, Fonderico M, Hemmer B, Derfuss T, et al
Impact of COVID-19 on multiple sclerosis care and management: Results from the European Committee for Treatment and Research in Multiple Sclerosis survey.
Mult Scler. 2021 Mar 25:13524585211005339. doi: 10.1177/13524585211005339.
PubMed Abstract available

LEE LE, Vavasour IM, Dvorak A, Liu H, et al
Cervical cord myelin abnormality is associated with clinical disability in multiple sclerosis.
Mult Scler. 2021 Mar 22:13524585211001780. doi: 10.1177/13524585211001780.
PubMed Abstract available

HARROUD A, Mitchell RE, Richardson TG, Morris JA, et al
Childhood obesity and multiple sclerosis: A Mendelian randomization study.
Mult Scler. 2021 Mar 22:13524585211001781. doi: 10.1177/13524585211001781.
PubMed Abstract available

BRIGGS FB, Krill D, Hill E, Conway DS, et al
Age of hypertension onset in multiple sclerosis patients.
Mult Scler. 2021 Mar 18:13524585211003016. doi: 10.1177/13524585211003016.
PubMed Abstract available

MASSAROTTI C, Sbragia E, Boffa G, Vercelli C, et al
Menstrual cycle resumption and female fertility after autologous hematopoietic stem cell transplantation for multiple sclerosis.
Mult Scler. 2021 Mar 12:13524585211000616. doi: 10.1177/13524585211000616.
PubMed Abstract available

SCHOONHEIM MM, Douw L, Broeders TA, Eijlers AJ, et al
The cerebellum and its network: Disrupted static and dynamic functional connectivity patterns and cognitive impairment in multiple sclerosis.
Mult Scler. 2021 Mar 8:1352458521999274. doi: 10.1177/1352458521999274.
PubMed Abstract available

MACHLANSKA A, Helbig G, Chromik K, Zapala M, et al
Hemophagocytic lymphohistiocytosis associated with ocrelizumab treatment in a patient with multiple sclerosis.
Mult Scler. 2021 Mar 5:1352458521993070. doi: 10.1177/1352458521993070.
PubMed Abstract available

LORSCHEIDER J
When does a heap become a heap?
Mult Scler. 2021;27:329-330.
PubMed

BUTZKUEVEN H, Trojano M, Kappos L, Spelman T, et al
Clinical outcomes in patients who discontinue natalizumab therapy after 2 years in the Tysabri((R)) Observational Program (TOP).
Mult Scler. 2021;27:410-419.
PubMed Abstract available

February 2021

SZILASIOVA J, Mikula P, Rosenberger J, Fedicova M, et al
Plasma neurofilament light chain levels are predictors of disease activity in multiple sclerosis as measured by four-domain NEDA status, including brain volume loss.
Mult Scler. 2021 Feb 26:1352458521998039. doi: 10.1177/1352458521998039.
PubMed Abstract available

FOX RJ, Raska P, Barro C, Karafa M, et al
Neurofilament light chain in a phase 2 clinical trial of ibudilast in progressive multiple sclerosis.
Mult Scler. 2021 Feb 26:1352458520986956. doi: 10.1177/1352458520986956.
PubMed Abstract available

COPETTI M, Liu D
Machine and deep learning in multiple sclerosis research are just powerful statistics - Commentary.
Mult Scler. 2021 Feb 24:1352458521996699. doi: 10.1177/1352458521996699.
PubMed

HARROUD A, Manousaki D, Butler-Laporte G, Mitchell RE, et al
The relative contributions of obesity, vitamin D, leptin, and adiponectin to multiple sclerosis risk: A Mendelian randomization mediation analysis.
Mult Scler. 2021 Feb 19:1352458521995484. doi: 10.1177/1352458521995484.
PubMed Abstract available

BINZER S, Jiang X, Hillert J, Manouchehrinia A, et al
Depression and multiple sclerosis: A bidirectional Mendelian randomisation study.
Mult Scler. 2021 Feb 19:1352458521996601. doi: 10.1177/1352458521996601.
PubMed Abstract available

LEMA DOPICO A, Choi S, Hua J, Li X, et al
Multi-layer analysis of quantitative 7 T magnetic resonance imaging in the cortex of multiple sclerosis patients reveals pathology associated with disability.
Mult Scler. 2021 Feb 18:1352458521994556. doi: 10.1177/1352458521994556.
PubMed Abstract available

HARROUD A, Marrie RA, Fitzgerald KC, Salter A, et al
Mendelian randomization provides no evidence for a causal role in the bidirectional relationship between depression and multiple sclerosis.
Mult Scler. 2021 Feb 16:1352458521993075. doi: 10.1177/1352458521993075.
PubMed Abstract available

BESSING B, Hussain MA, Claflin SB, Chen J, et al
Changes in multiple sclerosis symptoms are associated with changes in work productivity of people living with multiple sclerosis.
Mult Scler. 2021 Feb 16:1352458521994557. doi: 10.1177/1352458521994557.
PubMed Abstract available

BELVISI D, Canevelli M, Baione V, Buscarinu MC, et al
Operationalization of a frailty index in patients with multiple sclerosis: A cross-sectional investigation.
Mult Scler. 2021 Feb 10:1352458520987541. doi: 10.1177/1352458520987541.
PubMed Abstract available

MIDAGLIA L, Sastre-Garriga J, Pappolla A, Quibus L, et al
The frequency and characteristics of MS misdiagnosis in patients referred to the multiple sclerosis centre of Catalonia.
Mult Scler. 2021 Feb 10:1352458520988148. doi: 10.1177/1352458520988148.
PubMed Abstract available

VELDKAMP R, Kalron A, Baert I, Hamalainen P, et al
Differential effects and discriminative validity of motor and cognitive tasks varying in difficulty on cognitive-motor interference in persons with multiple sclerosis.
Mult Scler. 2021 Feb 10:1352458520986960. doi: 10.1177/1352458520986960.
PubMed Abstract available

KRASNIUK S, Classen S, Morrow SA, Alvarez L, et al
Clinical predictors of driving simulator performance in drivers with multiple sclerosis.
Mult Scler. 2021 Feb 10:1352458521992507. doi: 10.1177/1352458521992507.
PubMed Abstract available

DAS J, Snowden JA, Burman J, Freedman MS, et al
Autologous haematopoietic stem cell transplantation as a first-line disease-modifying therapy in patients with 'aggressive' multiple sclerosis.
Mult Scler. 2021 Feb 10:1352458520985238. doi: 10.1177/1352458520985238.
PubMed Abstract available

Incidence and clinical outcome of Coronavirus disease 2019 in a cohort of 11,560 Brazilian patients with multiple sclerosis.
Mult Scler. 2021 Feb 2:1352458520978354. doi: 10.1177/1352458520978354.
PubMed Abstract available

NYIRENDA MH, Fadda G, Healy LM, Mexhitaj I, et al
Pro-inflammatory adiponectin in pediatric-onset multiple sclerosis.
Mult Scler. 2021 Feb 1:1352458521989090. doi: 10.1177/1352458521989090.
PubMed Abstract available

YEH EA
Real-world outcomes in pediatric MS: Psychiatric comorbidities and school performance.
Mult Scler. 2021;27:165-166.
PubMed

SALTER A, Stahmann A, Ellenberger D, Fneish F, et al
Data harmonization for collaborative research among MS registries: A case study in employment.
Mult Scler. 2021;27:281-289.
PubMed Abstract available

January 2021

MANOUCHEHRINIA A, Kingwell E, Zhu F, Tremlett H, et al
A multiple sclerosis disease progression measure based on cumulative disability.
Mult Scler. 2021 Jan 25:1352458520988632. doi: 10.1177/1352458520988632.
PubMed Abstract available

JALUSIC KO, Ellenberger D, Rommer P, Stahmann A, et al
Effect of applying inclusion and exclusion criteria of phase III clinical trials to multiple sclerosis patients in routine clinical care.
Mult Scler. 2021 Jan 20:1352458520985118. doi: 10.1177/1352458520985118.
PubMed Abstract available

BLACK LJ, Hetherton S, Forkan M, Gonzales EG, et al
An exploratory study of diet in childhood and young adulthood and adult-onset multiple sclerosis.
Mult Scler. 2021 Jan 19:1352458520986964. doi: 10.1177/1352458520986964.
PubMed Abstract available

ROOS I, Leray E, Frascoli F, Casey R, et al
Determinants of therapeutic lag in multiple sclerosis.
Mult Scler. 2021 Jan 11:1352458520981300. doi: 10.1177/1352458520981300.
PubMed Abstract available

FITZGERALD KC, Damian A, Conway D, Mowry EM, et al
Vascular comorbidity is associated with lower brain volumes and lower neuroperformance in a large multiple sclerosis cohort.
Mult Scler. 2021 Jan 8:1352458520984746. doi: 10.1177/1352458520984746.
PubMed Abstract available

GONZALEZ-ESCAMILLA G, Groppa S
7 Tesla MRI will soon be helpful to guide clinical practice in multiple sclerosis centres - No.
Mult Scler. 2021 Jan 6:1352458520969662. doi: 10.1177/1352458520969662.
PubMed

SATI P, Reich DS
7 Tesla MRI will soon be helpful to guide clinical practice in multiple sclerosis centers - Commentary.
Mult Scler. 2021 Jan 6:1352458520981738. doi: 10.1177/1352458520981738.
PubMed

LOUAPRE C, Beigneux Y
7 Tesla MRI will soon be helpful to guide clinical practice in multiple sclerosis centres - Yes.
Mult Scler. 2021 Jan 6:1352458520972270. doi: 10.1177/1352458520972270.
PubMed

ROLLOT F, Casey R, Leray E, Debouverie M, et al
Cumulative effects of therapies on disability in relapsing multiple sclerosis.
Mult Scler. 2021 Jan 6:1352458520980366. doi: 10.1177/1352458520980366.
PubMed Abstract available

MARRIE RA, Leung S, Cutter GR, Fox RJ, et al
Comparative responsiveness of the health utilities index and the RAND-12 for multiple sclerosis.
Mult Scler. 2021 Jan 5:1352458520981370. doi: 10.1177/1352458520981370.
PubMed Abstract available

AMATO MP, Portaccio E, De Meo E
Understanding the pathophysiology of cognitive changes in MS: A step forward.
Mult Scler. 2021;27:4-5.
PubMed

BISTROM M, Hultdin J, Sundstrom P
Response to 'Mendelian randomization analysis does not support a role for leptin in multiple sclerosis'.
Mult Scler. 2021;27:161-162.
PubMed

AL-ARAJI S, Ciccarelli O
A possible case of serum sickness after ocrelizumab infusion - Commentary.
Mult Scler. 2021;27:158-159.
PubMed Abstract available

LIBERTINOVA J, Meluzinova E, Nema E, Rockova P, et al
Elevated D-dimer as an immediate response to alemtuzumab treatment.
Mult Scler. 2021;27:151-154.
PubMed Abstract available

ZHANG J, Giorgio A, Vinciguerra C, Stromillo ML, et al
Gray matter atrophy cannot be fully explained by white matter damage in patients with MS.
Mult Scler. 2021;27:39-51.
PubMed Abstract available

GEORGE IC, El Mendili MM, Inglese M, Azevedo CJ, et al
Cerebellar volume loss in radiologically isolated syndrome.
Mult Scler. 2021;27:130-133.
PubMed Abstract available

December 2020

NIELSEN NM, Gortz S, Hjalgrim H, Rostgaard K, et al
Maternal diabetes and risk of multiple sclerosis in the offspring: A Danish nationwide register-based cohort study.
Mult Scler. 2020 Dec 17:1352458520977120. doi: 10.1177/1352458520977120.
PubMed Abstract available

GALLO A, Bisecco A
Psychological resilience explains functional variability across people with multiple sclerosis - Commentary.
Mult Scler. 2020 Dec 17:1352458520978213. doi: 10.1177/1352458520978213.
PubMed

LEAVITT VM, Kever A
Psychological resilience explains functional variability across people with multiple sclerosis - Yes.
Mult Scler. 2020 Dec 17:1352458520972263. doi: 10.1177/1352458520972263.
PubMed

PLOUGHMAN M
Psychological resilience explains functional variability across people with multiple sclerosis - No.
Mult Scler. 2020 Dec 17:1352458520973633. doi: 10.1177/1352458520973633.
PubMed

COMABELLA M, Deutschmann C, Midaglia L, Schierack P, et al
Chitinase 3-like 1 is not a target antigen in patients with multiple sclerosis.
Mult Scler. 2020 Dec 17:1352458520980141. doi: 10.1177/1352458520980141.
PubMed Abstract available

HYLAND MH, Robb JF
Teleconsultation will replace most face-to-face interactions in the multiple sclerosis clinic - Yes.
Mult Scler. 2020 Dec 16:1352458520973640. doi: 10.1177/1352458520973640.
PubMed

MOCCIA M
Teleconsultation will replace most face-to-face interactions in the multiple sclerosis clinic - No.
Mult Scler. 2020 Dec 16:1352458520968815. doi: 10.1177/1352458520968815.
PubMed

D'HAESELEER M
Teleconsultation will replace most face-to-face interactions in the multiple sclerosis clinic - Commentary.
Mult Scler. 2020 Dec 16:1352458520979303. doi: 10.1177/1352458520979303.
PubMed

CALABRESI PA, Arnold DL, Sangurdekar D, Singh CM, et al
Temporal profile of serum neurofilament light in multiple sclerosis: Implications for patient monitoring.
Mult Scler. 2020 Dec 14:1352458520972573. doi: 10.1177/1352458520972573.
PubMed Abstract available

FILIPPATOU AG, Moniruzzaman M, Sotirchos ES, Fitzgerald KC, et al
Serum ceramide levels are altered in multiple sclerosis.
Mult Scler. 2020 Dec 14:1352458520971816. doi: 10.1177/1352458520971816.
PubMed Abstract available

CHAN CK, Tian F, Pimentel Maldonado D, Mowry EM, et al
Depression in multiple sclerosis across the adult lifespan.
Mult Scler. 2020 Dec 14:1352458520979304. doi: 10.1177/1352458520979304.
PubMed Abstract available

TAPIA-MALTOS MA, Trevino-Frenk I, Garcia-Gonzalez HB, Rosetti M, et al
Identification of regulatory T cell molecules associated with severity of multiple sclerosis.
Mult Scler. 2020 Dec 10:1352458520977045. doi: 10.1177/1352458520977045.
PubMed Abstract available

NAUTA IM, Kulik SD, Breedt LC, Eijlers AJ, et al
Functional brain network organization measured with magnetoencephalography predicts cognitive decline in multiple sclerosis.
Mult Scler. 2020 Dec 9:1352458520977160. doi: 10.1177/1352458520977160.
PubMed Abstract available

JACOBS BM, Smets I, Giovannoni G, Noyce A, et al
Regarding: Nicotinic acetylcholine receptors alpha7 and alpha9 modify tobacco smoke risk for multiple sclerosis.
Mult Scler. 2020 Dec 8:1352458520969941. doi: 10.1177/1352458520969941.
PubMed

BRIGGS F
Response to Jacobs et al, Nicotinic acetylcholine receptors alpha7 and alpha9 modify tobacco smoke risk for multiple sclerosis.
Mult Scler. 2020 Dec 8:1352458520977027. doi: 10.1177/1352458520977027.
PubMed

KOUBIYR I, Deloire M, Brochet B, Besson P, et al
Structural constraints of functional connectivity drive cognitive impairment in the early stages of multiple sclerosis.
Mult Scler. 2020 Dec 7:1352458520971807. doi: 10.1177/1352458520971807.
PubMed Abstract available

VUKUSIC S, Ionescu I, Cornu C, Bossard N, et al
Oral nomegestrol acetate and transdermal 17-beta-estradiol for preventing post-partum relapses in multiple sclerosis: The POPARTMUS study.
Mult Scler. 2020 Dec 3:1352458520978218. doi: 10.1177/1352458520978218.
PubMed Abstract available

RAMANUJAM R, Zhu F, Fink K, Karrenbauer VD, et al
Accurate classification of secondary progression in multiple sclerosis using a decision tree.
Mult Scler. 2020 Dec 2:1352458520975323. doi: 10.1177/1352458520975323.
PubMed Abstract available

SHAH S
Real-world evidence: One tweet at a time.
Mult Scler. 2020;26:1965-1966.
PubMed

COETZEE T, Thompson AJ
Atlas of MS 2020: Informing global policy change.
Mult Scler. 2020;26:1807-1808.
PubMed

PILUTTI LA, Fakolade A
Rehabilitation should be prescribed acutely in motor relapses - Commentary.
Mult Scler. 2020;26:1825-1827.
PubMed

November 2020

STEPHENS S, Berenbaum T, Finlayson M, Motl RW, et al
Youth with multiple sclerosis have low levels of fitness.
Mult Scler. 2020 Nov 27:1352458520974360. doi: 10.1177/1352458520974360.
PubMed Abstract available

ROMEO AR, Rowles WM, Schleimer ES, Barba P, et al
An electronic, unsupervised patient-reported Expanded Disability Status Scale for multiple sclerosis.
Mult Scler. 2020 Nov 25:1352458520968814. doi: 10.1177/1352458520968814.
PubMed Abstract available

LANGESKOV-CHRISTENSEN M, Hvid LG, Jensen HB, Nielsen HH, et al
Efficacy of high-intensity aerobic exercise on cognitive performance in people with multiple sclerosis: A randomized controlled trial.
Mult Scler. 2020 Nov 24:1352458520973619. doi: 10.1177/1352458520973619.
PubMed Abstract available

KLISTORNER S, Barnett MH, Yiannikas C, Barton J, et al
Expansion of chronic lesions is linked to disease progression in relapsing-remitting multiple sclerosis patients.
Mult Scler. 2020 Nov 20:1352458520974357. doi: 10.1177/1352458520974357.
PubMed Abstract available

IAFFALDANO P, Lucisano G, Patti F, Brescia Morra V, et al
Transition to secondary progression in relapsing-onset multiple sclerosis: Definitions and risk factors.
Mult Scler. 2020 Nov 19:1352458520974366. doi: 10.1177/1352458520974366.
PubMed Abstract available

LARONI A, Schiavetti I, Sormani MP, Uccelli A, et al
COVID-19 in patients with multiple sclerosis undergoing disease-modifying treatments.
Mult Scler. 2020 Nov 18:1352458520971817. doi: 10.1177/1352458520971817.
PubMed Abstract available

CREE BA, Magnusson B, Rouyrre N, Fox RJ, et al
Siponimod: Disentangling disability and relapses in secondary progressive multiple sclerosis.
Mult Scler. 2020 Nov 18:1352458520971819. doi: 10.1177/1352458520971819.
PubMed Abstract available

GLUKHOVSKY L, Kurz D, Brandstadter R, Leavitt VM, et al
Depression and cognitive function in early multiple sclerosis: Multitasking is more sensitive than traditional assessments.
Mult Scler. 2020 Nov 16:1352458520958359. doi: 10.1177/1352458520958359.
PubMed Abstract available

PREZIOSA P, Pagani E, Moiola L, Rodegher M, et al
Occurrence and microstructural features of slowly expanding lesions on fingolimod or natalizumab treatment in multiple sclerosis.
Mult Scler. 2020 Nov 13:1352458520969105. doi: 10.1177/1352458520969105.
PubMed Abstract available

HEITMANN H, Andlauer TFM, Korn T, Muhlau M, et al
Fatigue, depression, and pain in multiple sclerosis: How neuroinflammation translates into dysfunctional reward processing and anhedonic symptoms.
Mult Scler. 2020 Nov 12:1352458520972279. doi: 10.1177/1352458520972279.
PubMed Abstract available

SACCO R, Braga A, Disanto G, Digesu GA, et al
Effectiveness of percutaneous posterior tibial nerve stimulation for the management of bowel dysfunction in multiple sclerosis patients.
Mult Scler. 2020 Nov 12:1352458520972267. doi: 10.1177/1352458520972267.
PubMed Abstract available

KARIM ME, Pellegrini F, Platt RW, Simoneau G, et al
The use and quality of reporting of propensity score methods in multiple sclerosis literature: A review.
Mult Scler. 2020 Nov 12:1352458520972557. doi: 10.1177/1352458520972557.
PubMed Abstract available

AVILA M, Okai A, Thakolwiboon S, O'Bryan C, et al
The effect of tonsillectomy on John Cunningham virus serological status in multiple sclerosis patients: A retrospective case-control study.
Mult Scler. 2020 Nov 12:1352458520971822. doi: 10.1177/1352458520971822.
PubMed Abstract available

WALTON C, King R, Rechtman L, Kaye W, et al
Rising prevalence of multiple sclerosis worldwide: Insights from the Atlas of MS, third edition.
Mult Scler. 2020 Nov 11:1352458520970841. doi: 10.1177/1352458520970841.
PubMed Abstract available

HEDSTROM AK, Olsson T, Alfredsson L
Cotinine as a measure of smoking in observational studies of multiple sclerosis.
Mult Scler. 2020 Nov 10:1352458520968803. doi: 10.1177/1352458520968803.
PubMed Abstract available

LAM KH, Meijer KA, Loonstra FC, Coerver E, et al
Real-world keystroke dynamics are a potentially valid biomarker for clinical disability in multiple sclerosis.
Mult Scler. 2020 Nov 5:1352458520968797. doi: 10.1177/1352458520968797.
PubMed Abstract available

BUYUKTURKOGLU K, Zeng D, Bharadwaj S, Tozlu C, et al
Classifying multiple sclerosis patients on the basis of SDMT performance using machine learning.
Mult Scler. 2020 Nov 4:1352458520958362. doi: 10.1177/1352458520958362.
PubMed Abstract available

October 2020

LOZINSKI BM, Yong VW
Exercise and the brain in multiple sclerosis.
Mult Scler. 2020 Oct 30:1352458520969099. doi: 10.1177/1352458520969099.
PubMed Abstract available

AFZAL HMR, Luo S, Ramadan S, Lechner-Scott J, et al
The emerging role of artificial intelligence in multiple sclerosis imaging.
Mult Scler. 2020 Oct 28:1352458520966298. doi: 10.1177/1352458520966298.
PubMed Abstract available

PROSPERINI L, Haggiag S, Tortorella C, Galgani S, et al
Age-related adverse events of disease-modifying treatments for multiple sclerosis: A meta-regression.
Mult Scler. 2020 Oct 26:1352458520964778. doi: 10.1177/1352458520964778.
PubMed Abstract available

STRIK M, Chard DT, Dekker I, Meijer KA, et al
Increased functional sensorimotor network efficiency relates to disability in multiple sclerosis.
Mult Scler. 2020 Oct 26:1352458520966292. doi: 10.1177/1352458520966292.
PubMed Abstract available

KOSCH R, Schiffmann I, Daumer M, Lederer C, et al
Long-term prognostic counselling in people with multiple sclerosis using an online analytical processing tool.
Mult Scler. 2020 Oct 26:1352458520964774. doi: 10.1177/1352458520964774.
PubMed Abstract available

TECCHIO F, Bertoli M, Gianni E, L'Abbate T, et al
Parietal dysfunctional connectivity in depression in multiple sclerosis.
Mult Scler. 2020 Oct 21:1352458520964412. doi: 10.1177/1352458520964412.
PubMed

JAEGER S, Paul F, Finke C
Functional connectivity alterations of striato-cortical circuits in multiple sclerosis.
Mult Scler. 2020 Oct 21:1352458520966303. doi: 10.1177/1352458520966303.
PubMed

BERMEL RA, Fedler JK, Kaiser P, Novalis C, et al
Optical coherence tomography outcomes from SPRINT-MS, a multicenter, randomized, double-blind trial of ibudilast in progressive multiple sclerosis.
Mult Scler. 2020 Oct 15:1352458520964409. doi: 10.1177/1352458520964409.
PubMed Abstract available

MARRIE RA, Walld R, Bolton JM, Sareen J, et al
Effect of mood and anxiety disorders on health care utilization in multiple sclerosis.
Mult Scler. 2020 Oct 13:1352458520963880. doi: 10.1177/1352458520963880.
PubMed Abstract available

CASTELLI L, Quartuccio ME, Ruggieri S, De Giglio L, et al
'Posture second' strategy predicts disability progression in multiple sclerosis.
Mult Scler. 2020 Oct 13:1352458520963926. doi: 10.1177/1352458520963926.
PubMed Abstract available

VEREB D, Toth E, Bozsik B, Kiraly A, et al
Altered brain network function during attention-modulated visual processing in multiple sclerosis.
Mult Scler. 2020 Oct 5:1352458520958360. doi: 10.1177/1352458520958360.
PubMed Abstract available

LANGER-GOULD A, Black LJ, Waubant E, Smith JB, et al
Seafood, fatty acid biosynthesis genes, and multiple sclerosis susceptibility.
Mult Scler. 2020;26:1476-1485.
PubMed Abstract available

CHEN J, Taylor B, Winzenberg T, Palmer AJ, et al
Comorbidities are prevalent and detrimental for employment outcomes in people of working age with multiple sclerosis.
Mult Scler. 2020;26:1550-1559.
PubMed Abstract available

HULST HE, Penner IK
Cognition and its relation to brain health in patients with MS.
Mult Scler. 2020;26:1611-1613.
PubMed

HOBART J, Giovannoni G
Cognition and its relation to brain health in patients with MS: Response to letter.
Mult Scler. 2020;26:1613-1614.
PubMed

AZEVEDO CJ, Zamvil SS
New cases of vasculitis after alemtuzumab.
Mult Scler. 2020;26:1606-1608.
PubMed

September 2020

PISA M, Chieffo R, Congiu M, Dalla Costa G, et al
Intracortical motor conduction is associated with hand dexterity in progressive multiple sclerosis.
Mult Scler. 2020 Sep 25:1352458520960374. doi: 10.1177/1352458520960374.
PubMed Abstract available

FERRE L, Mogavero A, Clarelli F, Moiola L, et al
Early evidence of disease activity during fingolimod predicts medium-term inefficacy in relapsing-remitting multiple sclerosis.
Mult Scler. 2020 Sep 25:1352458520961690. doi: 10.1177/1352458520961690.
PubMed Abstract available

BOESEN MS, Blinkenberg M, Thygesen LC, Eriksson F, et al
School performance, psychiatric comorbidity, and healthcare utilization in pediatric multiple sclerosis: A nationwide population-based observational study.
Mult Scler. 2020 Sep 25:1352458520959673. doi: 10.1177/1352458520959673.
PubMed Abstract available

YAM C, Jokubaitis V, Hellwig K, Dobson R, et al
MS, pregnancy and COVID-19.
Mult Scler. 2020;26:1137-1146.
PubMed Abstract available

MECA-LALLANA V
COVID-19 will change MS care forever - Yes.
Mult Scler. 2020;26:1147-1148.
PubMed

PREZIOSA P, Rocca MA, Filippi M
COVID-19 will change MS care forever - No.
Mult Scler. 2020;26:1149-1151.
PubMed

August 2020

ABBOUD H
Iatrogenic demyelinating disorders: New insights, new culprits.
Mult Scler. 2020;26:1129-1130.
PubMed

June 2020

Household paired design reduces variance and increases power in multi-city gut microbiome study in multiple sclerosis.
Mult Scler. 2020 Jun 26:1352458520924594. doi: 10.1177/1352458520924594.
PubMed Abstract available

RICIGLIANO VA, Tonietto M, Palladino R, Poirion E, et al
Thalamic energy dysfunction is associated with thalamo-cortical tract damage in multiple sclerosis: A diffusion spectroscopy study.
Mult Scler. 2020 Jun 17:1352458520921362. doi: 10.1177/1352458520921362.
PubMed Abstract available

May 2020

BRUIJSTENS AL, Blok KM, Smolders J, Wokke BH, et al
Pediatric MS patients with a primary progressive-like disease may still have relevant inflammatory activity and may benefit from regular MS treatment.
Mult Scler. 2020 May 14:1352458520921367. doi: 10.1177/1352458520921367.
PubMed

March 2020

SMITH KA, Burkill S, Hiyoshi A, Olsson T, et al
Comorbid disease burden among MS patients 1968-2012: A Swedish register-based cohort study.
Mult Scler. 2020 Mar 12:1352458520910497. doi: 10.1177/1352458520910497.
PubMed Abstract available

LEITE MI, Sato DK
MOG-antibody-associated disease is different from MS and NMOSD and should be considered as a distinct disease entity - Yes.
Mult Scler. 2020;26:272-274.
PubMed

COBO-CALVO A, Marignier R
MOG-antibody-associated disease is different from MS and NMO and should be considered as a distinct disease entity - No.
Mult Scler. 2020;26:274-276.
PubMed

DURAND-DUBIEF F, Marignier R, Berthezene Y, Cottin J, et al
Spontaneous multiple cervical artery dissections after alemtuzumab.
Mult Scler. 2020;26:381-383.
PubMed Abstract available

CHIARAVALLOTI ND, Moore NB, DeLuca J
The efficacy of the modified Story Memory Technique in progressive MS.
Mult Scler. 2020;26:354-362.
PubMed Abstract available

February 2020

MCKEON A, Zekeridou A
Autoimmune encephalitis management: MS centers and beyond.
Mult Scler. 2020 Feb 13:1352458520905485. doi: 10.1177/1352458520905485.
PubMed Abstract available

THOMPSON AJ, Cohen JA, Kim HJ, Geurts J, et al
MSJ 2020 - Editorial comment.
Mult Scler. 2020;26:134.
PubMed

LUBLIN F
Real-world studies provide reliable comparisons of disease modifying therapies in MS - Commentary.
Mult Scler. 2020;26:163-164.
PubMed

SORMANI MP
Real-world studies provide reliable comparisons of disease modifying therapies in MS - No.
Mult Scler. 2020;26:161-162.
PubMed

KALINCIK T
Real-world studies provide reliable comparisons of disease modifying therapies in MS - Yes.
Mult Scler. 2020;26:159-161.
PubMed

January 2020

WARNKE C, Hartung HP
Big data in MS-What can we learn from large international observational studies such as MSBase?
Mult Scler. 2020;26:4-5.
PubMed

REDDEL SW
Clinical commentary on 'Post-mortem diagnosis of invasive pulmonary aspergillosis after alemtuzumab treatment for multiple sclerosis'.
Mult Scler. 2020;26:126-127.
PubMed

VUKUSIC S, Casey R, Rollot F, Brochet B, et al
Observatoire Francais de la Sclerose en Plaques (OFSEP): A unique multimodal nationwide MS registry in France.
Mult Scler. 2020;26:118-122.
PubMed Abstract available

MELI R, Roccatagliata L, Capello E, Bruschi N, et al
Ecological impact of isolated cognitive relapses in MS.
Mult Scler. 2020;26:114-117.
PubMed Abstract available

November 2019

COMI G, Alroughani R, Boster AL, Bass AD, et al
Efficacy of alemtuzumab in relapsing-remitting MS patients who received additional courses after the initial two courses: Pooled analysis of the CARE-MS, extension, and TOPAZ studies.
Mult Scler. 2019 Nov 25:1352458519888610. doi: 10.1177/1352458519888610.
PubMed Abstract available

BOESEN F, Norgaard M, Skjerbaek AG, Rasmussen PV, et al
Can inpatient multidisciplinary rehabilitation improve health-related quality of life in MS patients on the long term - The Danish MS Hospitals Rehabilitation Study.
Mult Scler. 2019 Nov 5:1352458519884244. doi: 10.1177/1352458519884244.
PubMed Abstract available

June 2019

GHEZZI L, Cantoni C, Cignarella F, Bollman B, et al
T cells producing GM-CSF and IL-13 are enriched in the cerebrospinal fluid of relapsing MS patients.
Mult Scler. 2019 Jun 25:1352458519852092. doi: 10.1177/1352458519852092.
PubMed Abstract available

March 2019

MEYER CE, Gao JL, Cheng JY, Oberoi MR, et al
Axonal damage in spinal cord is associated with gray matter atrophy in sensorimotor cortex in experimental autoimmune encephalomyelitis.
Mult Scler. 2019 Mar 7:1352458519830614. doi: 10.1177/1352458519830614.
PubMed Abstract available

February 2019

CUKER A, Bass AD, Nadj C, Agius MA, et al
Immune thrombocytopenia in alemtuzumab-treated MS patients: Incidence, detection, and management.
Mult Scler. 2019 Feb 20:1352458518816612. doi: 10.1177/1352458518816612.
PubMed Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Multiple Sclerosis is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: